HELP     Sign In
Search

Relevance to Autism

According to a review (Dykens and Volkmar, 1997) of 14 studies, the percentages of individuals with Fragile X syndrome who met criteria for autism varied from 5 to 60%, with 7 studies finding more than 20%. As well, polymorphisms in the FMR1 gene have been found to be associated with autism. However, other studies have found no genetic association or only relatively rare identification of FMR1 with autism. Separately, several studies have found a CGG repeat polymorphism as well as rare variations in the FMR1 gene identified with Fragile X syndrome and general cognitive function.

Molecular Function

The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm.

External Links

        

References

Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmenta...
Fragile X syndrome
ASD, DD
Negative Association
Molecular and cytogenetic investigations of the fragile X region including the Frax A and Frax E CGG trinucleotide repeat sequences in families mul...
ASD
Negative Association
ASD
Negative Association
Association and transmission analysis of the FMR1 IVS10 14C-T variant in autism.
ASD
Support
Fragile X syndrome
Support
A novel fragile X syndrome mutation reveals a conserved role for the carboxy-terminus in FMRP localization and function.
Fragile X syndrome
ID
Support
DD, ID
ADHD, epilepsy/seizures, autistic features
Support
Maturation Delay of Human GABAergic Neurogenesis in Fragile X Syndrome Pluripotent Stem Cells
Fragile X syndrome
Support
Fragile X syndrome
Support
Fmrp regulates neuronal balance in embryonic motor circuit formation
Support
Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing.
ID
Support
Genetic care in geographically isolated small island communities: 8 years of experience in the Dutch Caribbean
ID
DD, epilepsy/seizures, stereotypy
Support
Fragile X syndrome
Support
Fragile X Syndrome Patient-Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes
Fragile X syndrome
Support
Massively parallel sequencing of patients with intellectual disability, congenital anomalies and/or autism spectrum disorders with a targeted gene ...
DD, ID, ASD
MCA
Support
Fragile X syndrome, ASD
Support
Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability.
ID
Support
ADHD, DD, ID
Support
Molecular convergence between Down syndrome and fragile X syndrome identified using human pluripotent stem cell models
Fragile X syndrome
Support
Fragile X syndrome due to a missense mutation.
Fragile X syndrome
ADHD
Support
Point mutation analysis of the FMR-1 gene in autism.
ASD
Support
Fragile X syndrome
Support
Comprehensive Analysis of Rare Variants of 101 Autism-Linked Genes in a Hungarian Cohort of Autism Spectrum Disorder Patients.
ASD
Fragile X syndrome
Support
Fragile X syndrome
Support
Integrating de novo and inherited variants in 42
ASD
Support
Using whole-exome sequencing to identify inherited causes of autism.
ASD
Support
A point mutation in the FMR-1 gene associated with fragile X mental retardation.
ID
Support
Fragile X syndrome
Support
Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features.
Fragile X syndrome
Support
Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome
Fragile X syndrome
Support
A nonsense mutation in FMR1 causing fragile X syndrome.
Fragile X syndrome
ID, epilepsy, autistic features
Support
Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome.
ID
Support
Fragile X syndrome, ASD
Support
Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome.
Fragile X syndrome
Support
Fragile X syndrome
Support
De Novo Large Deletion Leading to Fragile X Syndrome
Fragile X syndrome
ADHD, DD, ID
Support
Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males.
DD
Support
Fragile X syndrome
Highly Cited
Autism: the point of view from fragile X studies.
Fragile X syndrome
ASD
Highly Cited
The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein.
Recent Recommendation
A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.
Recent Recommendation
Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP.
Recent Recommendation
Role of CTCF protein in regulating FMR1 locus transcription.
Recent Recommendation
Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models.
Recent Recommendation
Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack.
Recent Recommendation
Enhanced asynchronous Ca(2) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expa...
Recent Recommendation
A novel function for fragile X mental retardation protein in translational activation.
Recent Recommendation
Genome-wide detection of tandem DNA repeats that are expanded in autism
ASD
Fragile X syndrome
Recent Recommendation
A functional requirement for PAK1 binding to the KH(2) domain of the fragile X protein-related FXR1.
Recent Recommendation
FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels.
Recent Recommendation
Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.
Recent Recommendation
Sumoylation regulates FMRP-mediated dendritic spine elimination and maturation.
Recent Recommendation
Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice.
Recent Recommendation
Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95.
Recent Recommendation
FMRP acts as a key messenger for dopamine modulation in the forebrain.
Recent Recommendation
A 3' untranslated region variant in FMR1 eliminates neuronal activity-dependent translation of FMRP by disrupting binding of the RNA-binding protei...
Recent Recommendation
Dysregulation of mTOR signaling in fragile X syndrome.
Recent Recommendation
FMRP targets distinct mRNA sequence elements to regulate protein expression.
Recent Recommendation
Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS).
Fragile X-associated tremor/ataxia syndrome
Recent Recommendation
Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures.
Recent Recommendation
Mouse model of fragile X syndrome: behavioral and hormonal response to stressors.
Recent Recommendation
High-functioning autism spectrum disorder and fragile X syndrome: report of two affected sisters.
ASD
Recent Recommendation
mRNPs, polysomes or granules: FMRP in neuronal protein synthesis.
Recent Recommendation
FMRP regulates multipolar to bipolar transition affecting neuronal migration and cortical circuitry.
Recent Recommendation
Ca2????dependent protein kinase IV links group I metabotropic glutamate receptors to fragile X mental retardation protein in cingulate cor...

Rare

Variant ID
Variant Type
Allele Change
Residue Change
Inheritance Pattern
Inheritance Association
Family Type
Author, Year
 GEN093R001 
 synonymous_variant 
 c.138G>A 
 p.(=) 
  
  
  
 GEN093R002 
 intron_variant 
  
  
  
  
  
 GEN093R003 
 intron_variant 
  
  
  
  
  
 GEN093R004 
 missense_variant 
 c.1100T>A 
 p.Ile367Asn 
 De novo 
  
 Simplex 
 GEN093R005 
 frameshift_variant 
 c.373del 
 p.Thr125LeufsTer35 
 De novo 
  
  
 GEN093R006 
 splice_site_variant 
 23714GG-TA 
  
 Familial 
 Maternal 
  
 GEN093R007 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
 c.-129_-127CGG(450) 
  
 Familial 
 Maternal 
 Multiplex 
 GEN093R008 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
 c.-129_-127CGG(370) 
  
 Familial 
 Maternal 
 Multiplex 
 GEN093R009 
 missense_variant 
 c.1506A>G 
 p.Leu502= 
 Familial 
 Maternal 
 Simplex 
 GEN093R010 
 missense_variant 
 c.1079A>G 
 p.Glu360Gly 
 Familial 
 Maternal 
  
 GEN093R011 
 stop_gained 
 c.80C>A 
 p.Ser27Ter 
 Familial 
 Maternal 
 Simplex 
 GEN093R012 
 missense_variant 
 c.413G>A 
 p.Arg138Gln 
 Familial 
 Maternal 
 Simplex 
 GEN093R013 
 2KB_upstream_variant 
 c.-332G>C 
  
 Unknown 
  
 Unknown 
 GEN093R014 
 2KB_upstream_variant 
 c.-293T>C 
  
 Unknown 
  
 Unknown 
 GEN093R015 
 2KB_upstream_variant 
 c.1A>G 
 p.Met1? 
 Unknown 
  
 Unknown 
 GEN093R016 
 splice_site_variant 
 c.880+885A>G 
  
 Unknown 
  
 Unknown 
 GEN093R017 
 splice_site_variant 
 c.1189-467C>G 
  
 Unknown 
  
 Unknown 
 GEN093R018 
 copy_number_loss 
  
  
 Familial 
 Maternal 
 Multiplex 
 GEN093R019 
 frameshift_variant 
 c.1457_1458insG 
 p.Gly487TrpfsTer7 
 Unknown 
  
 Simplex 
 GEN093R020 
 intron_variant 
 c.-133A>C 
  
 Unknown 
  
 Unknown 
 GEN093R021 
 3_prime_UTR_variant 
 c.518T>C 
 p.Ile173Thr 
 Unknown 
  
 Unknown 
 GEN093R022 
 3_prime_UTR_variant 
 c.*1867G>A 
  
 Unknown 
  
 Unknown 
 GEN093R023 
 intron_variant 
 c.419+420A>C 
  
 Unknown 
  
 Unknown 
 GEN093R024 
 intron_variant 
 c.631-840G>A 
  
 Unknown 
  
 Unknown 
 GEN093R025 
 intron_variant 
 c.990+4T>C 
  
 Unknown 
  
 Unknown 
 GEN093R026 
 3_prime_UTR_variant 
 c.*23T>C 
  
 Unknown 
  
 Unknown 
 GEN093R027 
 3_prime_UTR_variant 
 c.*2035C>T 
  
 Unknown 
  
 Unknown 
 GEN093R028 
 missense_variant 
 c.797G>A 
 p.Gly266Glu 
 Familial 
 Maternal 
 Simplex 
 GEN093R029 
 splice_site_variant 
 c.990+1G>A 
  
 De novo 
  
 Simplex 
 GEN093R030 
 splice_site_variant 
 c.183A>G 
 p.Glu61= 
 Familial 
 Maternal 
 Simplex 
 GEN093R031 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Unknown 
  
  
 GEN093R032 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Familial 
 Maternal 
  
 GEN093R033 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Familial 
 Maternal 
  
 GEN093R034 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Unknown 
  
  
 GEN093R035 
 missense_variant 
 c.1816C>T 
 p.Arg606Cys 
 Familial 
 Maternal 
 Unknown 
 GEN093R036 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 De novo 
  
 Simplex 
 GEN093R037 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 De novo 
  
 Simplex 
 GEN093R038 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Familial 
 Maternal 
 Simplex 
 GEN093R039 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 De novo 
  
 Simplex 
 GEN093R040 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Familial 
 Maternal 
 Simplex 
 GEN093R041 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Unknown 
  
 Unknown 
 GEN093R042 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Unknown 
  
  
 GEN093R043 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Unknown 
  
  
 GEN093R044 
 copy_number_loss 
  
  
 De novo 
  
  
 GEN093R045 
 splice_site_variant 
 c.270+1G>A 
  
 De novo 
  
  
 GEN093R046 
 frameshift_variant 
 c.1007dup 
 p.Asn336LysfsTer7 
 De novo 
  
 Simplex 
 GEN093R047 
 missense_variant 
 c.866C>T 
 p.Pro289Leu 
 De novo 
  
  
 GEN093R048 
 frameshift_variant 
 c.1268_1269del 
 p.Tyr423PhefsTer15 
 De novo 
  
  
 GEN093R049 
 missense_variant 
 c.1448A>G 
 p.Gln483Arg 
 Familial 
 Maternal 
  
 GEN093R050 
 trinucleotide_repeat_microsatellite_feature, 5_prime_UTR_variant 
  
  
 Unknown 
  
 Multiplex 
  et al.  

Common

No Common Variants Available
Chromosome
CNV Locus
CNV Type
# of studies
Animal Model
X
Deletion
 1
 
X
Duplication
 1
 
X
Deletion-Duplication
 21
 
X
Deletion
 2
 
X
Deletion
 1
 
X
Deletion
 1
 
X
Deletion-Duplication
 1
 
X
Deletion
 2
 
X
Deletion-Duplication
 1
 
X
Deletion
 1
 
X
Deletion-Duplication
 13
 
X
Deletion
 10
 

Model Summary

Fragile X Syndrome.

References

Type
Title
Author, Year
Additional
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome.
Additional
Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model.
Additional
The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo.
Additional
Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein.
Additional
Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities.
Additional
Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice.
Additional
Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus.
Additional
Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.
Additional
Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome.
Additional
A mouse model of the human Fragile X syndrome I304N mutation.
Additional
Dysregulation of mTOR signaling in fragile X syndrome.
Additional
GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism.
Additional
A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis.
Additional
Hyperconnectivity and slow synapses during early development of medial prefrontal cortex in a mouse model for mental retardation and autism.
Additional
Reversal of fragile X phenotypes by manipulation of APP/A levels in Fmr1KO mice.
Additional
The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.
Additional
Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.
Additional
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
Additional
Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, ...
Additional
Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Additional
Reorganization of circuits underlying cerebellar modulation of prefrontal cortical dopamine in mouse models of autism spectrum disorder.
Additional
Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Additional
Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Additional
Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model.
Additional
Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.
Additional
Hyperactivity and lack of social discrimination in the adolescent Fmr1 knockout mouse.
Additional
Convergence of Hippocampal Pathophysiology in Syngap and Fmr1-/y Mice.
Additional
Peripheral Mechanosensory Neuron Dysfunction Underlies Tactile and Behavioral Deficits in Mouse Models of ASDs.
Additional
Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition.
Additional
Adult Fmr1 knockout mice present with deficiencies in hippocampal interleukin-6 and tumor necrosis factor- expression.
Additional
Chronic minocycline treatment improves hippocampal neuronal structure, NMDA receptor function, and memory processing in Fmr1 knockout mice.
Additional
Striatal Inhibition of MeCP2 or TSC1 Produces Sociability Deficits and Repetitive Behaviors.
Additional
Increased Excitation-Inhibition Ratio Stabilizes Synapse and Circuit Excitability in Four Autism Mouse Models.
Additional
Targeting Peripheral Somatosensory Neurons to Improve Tactile-Related Phenotypes in ASD Models.
Additional
IL-17a Promotes Sociability in Mouse Models of Neurodevelopmental Disorders
Additional
Elevated protein synthesis in microglia causes autism-like synaptic and behavioral aberrations
Additional
ATP Synthase c-Subunit Leak Causes Aberrant Cellular Metabolism in Fragile X Syndrome
Additional
Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
Additional
Parallel Social Information Processing Circuits Are Differentially Impacted in Autism
Primary
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium.
Primary
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits.

M_FMR1_10_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Purkinje cell specific knock out of FMR1, using L7-cre mice.
Allele Type: Knockout
Strain of Origin:
Genetic Background: mixed
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_FMR1_1_KO_HM

Model Type: Genetic
Model Genotype: Homozygous; hemizygous
Mutation: FMR1 mutant gene was generated by construction a targeting vector using homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin (neo). FMR1 homozygous knockout mice (FMR1^tm1Cgr) were bred with NeuroD1 bacTRAP (ND1-BT) heterozygous mice (PMID 28823556) to generate FMR1 and ND-BT1 dual heterozygous female mice that were bred with FMR1-/y male mice to generate FMR1 null and ND1-BT heterozygous (FMR1-/-;ND1-BT+/-) that were used for experimentations.
Allele Type: Knockout
Strain of Origin: 129P2/OlaHsd
Genetic Background: C57BL/6J
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: The Jackson Laboratory

M_FMR1_3_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: A germline null mutation was created by crossing FMR1 mice, which has the first coding exon floxed, with mice that express Cre-recombinase in the germline (Tg(CAG-cre)13Miya). Gene inactivation was confirmed by a lack of protein expression in the brain and testes as determined by immunoblot analysis.
Allele Type: Knockout
Strain of Origin: C57BL/6J
Genetic Background: 129P2/OlaHsd * C57BL/6
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: Not Specified

M_FMR1_4_CKO_HM_PURKINJEN

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Conditional deletion of exon 1 of FMR1 using L7-cre, in Purkinje cells of the cerebellum
Allele Type: Conditional loss-of-function
Strain of Origin: C57BL/6J
Genetic Background: Not specified
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: Not Specified

M_FMR1_9_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: FMR1 KO mice, floxed at exon 5, maintained in the mixed background of C57Bl/6 and 129P2.
Allele Type: Knockout
Strain of Origin:
Genetic Background: C57BL/6.129P2
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_FMR1_2_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: FMR1 gene was generated by construction a targeting vector using homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin (neo).
Allele Type: Knockout
Strain of Origin: 129P2/OlaHsd
Genetic Background: Not Specified
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: Not Specified

M_FMR1_6_KI_HM_I304N

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Homologous recombination mediated introduction of I304N mutation to FMR1 locus.
Allele Type: Humanized LOF mutation
Strain of Origin: Not Specified
Genetic Background: FVB x C57BL/6J
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

M_FMR1_11_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: FMR1 KO mice with a mixed FVB and 129P2 background(information not available for pde6b+.
Allele Type: Knockout
Strain of Origin:
Genetic Background: FVB.129P2
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_FMR1_5_KI_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Knock in of transgene containing ~120 CGG.CCG repeats in the FMR1 gene with a Cre recombinase under the control of the MMTV promoter.
Allele Type: Humanized LOF mutation
Strain of Origin: Not Specified
Genetic Background: C57BL/6
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

M_FMR1_8_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: FMR1 KO mice were originally on the C57Bl/6 background but to generate phenotyped in a mixed C57BL/6 129SveJ background form litters.
Allele Type: Knockout
Strain of Origin:
Genetic Background: C57BL/6.129SVeJ
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_FMR1_7_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin, maintained in a mixed background with FVB and 129P2 corrected for eyesight by the pde6b allele.
Allele Type: Knockout
Strain of Origin: Not Specified
Genetic Background: FVB.129P2.pde6b+
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

M_FMR1_1_KO_HM_5HT2BAG+D1AG+PI3KINHIBITOR

Model Type: Pharmaceutical intervention
Model Genotype: Homozygous
Mutation: Postnatal day 14 to 29 d old mice were anesthetized by an i.p. injection of 10mg/kg ketamine and 2mg/kg xylazine. A GluA1-GFP viral contruct was injected through a glass pipette, stereotaxically into the hippocampal CA1 region. For behavioral tests 10-12 injections of 6 ul high titer viral solutions were delivered along the entire hippocampus of both sides to achieve expression in one third of the CA1 pyramidal neurons. A cocktail of 5HT and Dopamine receptor agonist and antagonist was coadministered. The 5HT 2B-R agonist BW723C86 (0.05mg/kg) and 5HT 2A-R-Antagonist MDL11939 (0.01mg/kg)The D1- R agonist SKF81297 (0.05mg/kg) and D2-R antagonist Sulpiride (0.25mg/kg) were administered by four i.p. injections spaced by 4-6 h. The administration started 4-10 h before the viral injection and 16-20 h before behavioral tests. The compounds were dissolved in saline and saline was given to vehicle controls.
Allele Type: Knockout
Strain of Origin: 129P2/OlaHsd
Genetic Background: C57BL/6
ES Cell Line:
Mutant ES Cell Line:
Model Source: JAX

M_FMR1_1_KO_HM_GLUA1CT-5HT2BAG+D1AG

Model Type: Pharmaceutical intervention
Model Genotype: Homozygous
Mutation: Postnatal day 14 to 29 d old mice were anesthetized by an i.p. injection of 10mg/kg ketamine and 2mg/kg xylazine. A GluA1ct-GFP viral contruct was injected through a glass pipette, stereotaxically into the hippocampal CA1 region. The GluA!ct is a GFP taged cytiplasmic domain of GluA1 receptor subunit that acts as a dominant negative construct selectively blocking synaptic trafficking of endogenous or viral GluA1 contianing AMPA-rs.
Allele Type: Knockout
Strain of Origin: 129P2/OlaHsd
Genetic Background: C57BL/6
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_SYNGAP1_9_KO_FMR1_DM

Model Type: Genetic
Model Genotype: Hemizygous (Fmr1), heterozygous (Syngap1)
Mutation: Syngap1 het mice were mated with FMR1-/+ females to get FMR1-/y:Syngap1+/- mice.
Allele Type: Knockout
Strain of Origin: 129P2/OlaHsd*C57BL/6JOla
Genetic Background:
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_FMR1_12_KO_HM

Model Type: Genetic
Model Genotype: Homozygous; hemizygous
Mutation: FMR1 knockout mice on the FVB/NJ background. (Construct details not available).
Allele Type: Knockout
Strain of Origin: Not Specified
Genetic Background: FVB/NJ
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Lugo Lab, Baylor University (PMID 28915148)

M_FMR1_13_KD

Model Type: Genetic
Model Genotype: Wildtype
Mutation: Seven-week-old wildtype C57BL/6 male mice were injected with Fmr1-siRNA (1358762, NM_008031.2), bilaterally in the dorsal striatum using a stereotaxic apparatus, resulting in a reduction of Fmr1 transcript levels to 0.4 fold compared with control siRNA injected mice.
Allele Type: Knockdown
Strain of Origin: C57BL/6
Genetic Background: C57BL/6
ES Cell Line: NA
Mutant ES Cell Line: NA
Model Source: Daehan BioLink (Eumsung, Chungbuk, Republic of Korea)

M_FMR1_14_KO_HE

Model Type: Genetic
Model Genotype: Homozygous/Hemizygous
Mutation: FMR1 mutant gene was generated by construction a targeting vector using homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin (neo). FMR1 homozygous knockout mice (FMR1^tm1Cgr) were bred with NeuroD1 bacTRAP (ND1-BT) heterozygous mice (PMID 28823556) to generate FMR1 and ND-BT1 dual heterozygous female mice that were bred with FMR1-/y male mice to generate FMR1 null and ND1-BT heterozygous (FMR1-/-;ND1-BT /-) that were used for experimentations; M_FMR1_1_KO_HM
Allele Type: Knockout
Strain of Origin:
Genetic Background: C57BL/6J*129/SvEv*CD1
ES Cell Line:
Mutant ES Cell Line:
Model Source: Not specified

M_FMR1_15_KO_HM

Model Type: Genetic LOF
Model Genotype: Homozygous
Mutation: Fmr1 ko mice with a deletion of the promotor and the first exon.
Allele Type: Knockout
Strain of Origin: C57BL/6J
Genetic Background: C57BL/6J
ES Cell Line:
Mutant ES Cell Line:
Model Source:

M_FMR1_10_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Spontaneous movement1
Increased
Description: Significantly more crossings in an empty cage
Exp Paradigm: Number of crossing through trhee infrared beams in an empty cage
 Home cage behavior
 Unreported
Social interaction1
Increased
Description: No difference in time spent in each compartment however much more line crossings in the lit compartment
Exp Paradigm: Movement in and between two compartments (one lit and one dark) of a box
 Light-dark exploration test
 Unreported
Size/growth1
Increased
Description: Increased testicular weight without structural differences at four different ages; total weight and weight of kidney, heart, spleen, and liver were not statstically different
Exp Paradigm: General observation; light microscopic examination
 Measurement of tissue weight
 5-7 weeks, 2.5 months; 3.5 months; 5.5 months
Spatial learning1
Decreased
Description: Highly significant decrease in escape latency
Exp Paradigm: Hidden platform condition of morris water maze task
 Morris water maze test
 Unreported
Reproductive system development1
 No change
 General observations
 Unreported
Cued or contextual fear conditioning1
 No change
 Fear conditioning test
 Unreported
Spatial learning1
 No change
 Morris water maze test
 Unreported
Brain size1
 No change
 Measurement of tissue weight
 2 months
Social interaction1
 No change
 Reciprocal social interaction test
 Unreported
 Not Reported: Circadian sleep/wake cycle, Communications, Emotion, Immune response, Maternal behavior, Molecular profile, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory

M_FMR1_1_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity12
Increased
Description: The juvenile fmr1 ko mice show increased hyperactivity in the open field test measured by the number of line crossings
Exp Paradigm: Three-chamber social approach test
 Three-chamber social approach test
 7-10 weeks
General locomotor activity9
Increased
Description: Increased novelty-induced locomotor activity
Exp Paradigm: Open field test
 Open field test
 2-5 months
Hyperactivity12
Increased
Description: The juvenile fmr1 ko mice show increased hyperactivity in the open field test measured by the number of line crossings
Exp Paradigm: Open field test
 Open field test
 7-10 weeks
General locomotor activity4
Increased
Description: Increased general locomotor activity indicated by increased travel distance, travel speed, no. of line crossings, distance travelled in centre zone
Exp Paradigm: Open field test
 Open field test
 2.5 - 6 months
General locomotor activity: ambulatory activity13
Increased
Description: Fmr1 knockout mice show increase in distance travelled compared to controls.
Exp Paradigm: Open field test
 Open field test
 4-8 weeks
Swimming ability4
Increased
Description: Increased swimming speed indicative of hyperactivity
Exp Paradigm: Swimming test
 Swim test
 2.5 - 6 months
General locomotor activity: ambulatory activity13
Increased
Description: Fmr1 knockout mice show increase in distance travelled compared to controls.
Exp Paradigm: Novel object recognition test
 Novel object recognition test
 4-8 weeks
Dendritic architecture: spine density16
Increased
Description: The apical dendrites of layer v pyramidal neurons from visual cortex of fmr1 ko mice have higher spine density than wild type mice
Exp Paradigm: Quantification using light microscope of sections fixed and mounted after being impregnated with golgi-cox
 Immunohistochemistry
 8 weeks
Synapse density4
Increased
Description: Increased numbers of inhibitory synapses as indicated by puncta positive for gephyrin and vgat
Exp Paradigm: Immunostaining analysis for gephyrin and vgat
 Immunohistochemistry
 2.5 - 6 months
Dendritic architecture: dendritic length14
Decreased
Description: Mutants show decrease in dendritic length compared to controls. mutants show no change in the dendritic length per branch order compared to controls.
Exp Paradigm: Dendritic complexity was quantified using dendritic length, number of intersections within sholl radii (10m concentric circles), and mean dendritic length/number of branches per branch order. cells were filled with biocytin to vidualize dendrites.
 Sholl analysis
 Adult
Microglial number18
Increased
Description: Increased microglial density in striatum; no change in microglial density in the mpfc, hip and str at 6 weeks
Exp Paradigm: NA
 Immunohistochemistry
 2 weeks
Dendritic architecture: spine density9
Increased
Description: Increased spine density in pyramidal neurons of binocular visual cortex in basal dendrites
Exp Paradigm: Golgi analysis
 Golgi-cox staining
 Unreported
Synapse density4
Decreased
Description: Decreased numbers of excitatory synapses as indicated by puncta positive for psd95 and vglut
Exp Paradigm: Immunostaining analysis for psd95 and vglut
 Immunohistochemistry
 2.5 - 6 months
Brain development3
Decreased
Description: Decreased neuronal cell survival in the ventral dentate gyrus
Exp Paradigm: Brdu immunohistochemical analysis
 Immunohistochemistry
 Unreported
Microglial morphology18
Increased
Description: Increase in size of microglia in mpfc, hip, str at 2 weeks; no change in microglial size at 6 weeks
Exp Paradigm: NA
 Immunohistochemistry
 2 weeks
Dendritic architecture: spine density13
Increased
Description: Fmr1 knockout mice show increase in the density of spines in cortical neurons compared to controls.
Exp Paradigm: NA
 Immunohistochemistry
 4-8 weeks
Neuroreceptor levels: glutamate receptors: nmda receptors14
Decreased
Description: Mutants show decrease in nmda receptor subunits glun1, glun2a, and glun2b compared to controls.
Exp Paradigm: NA
 Western blot
 Adult
Hypothalamic morphology17
Decreased
Description: Disruption of normal functioning of parvocellular oxytocin neurons (fluoro-gold nagative, shoulder negative based on shape of membrane depolarization preceeding action potential) but not magnocellular oxytocin neurons (fluoro gold positive) in the pvn of the hypothalamus
 Immunohistochemistry
 3 - 7 weeks
Dendritic architecture: dendritic tree complexity14
Decreased
Description: Mutants show decrease in the number of intersections and dendritic branchings, compared to controls. mutants show a decrease in the number of dendritic branches in the tertiary branch order, compared to controls.
Exp Paradigm: Dendritic complexity was quantified using dendritic length, number of intersections within sholl radii (10m concentric circles), and mean dendritic length/number of branches per branch order. cells were filled with biocytin to vidualize dendrites.
 Sholl analysis
 Adult
Morphology of the basal ganglia: Ventral striatum or nucleus accumbens17
Abnormal
Description: Fmr1 in ot neurons projecting to the nac specifically is required for peer-peer social reward learning
 Retrograde labeling assay
 3 - 7 weeks
Synaptic plasticity: ltd9
Increased
Description: Increased gp1 mglu-mediated hippocampal ltd
Exp Paradigm: Extracellular field potentials were recorded in stratum radiatum of ca1 in response to schaffer collateral stimulation from hippocampal slices
 Field potential recordings
 3-4 weeks
Synaptic neuroreceptor ratio (nmdar/ampar) dependent transmission14
Decreased
Description: Mutants show increased ampa/nmda ratio compared to controls.
Exp Paradigm: NA
 Whole-cell voltage clamp
 Adult
Neuronal activation15
Increased
Description: Mutant mice show increase in the number of fos positive cells in the s1dz.
Exp Paradigm: Fos
 Immunohistochemistry
 Adult, 2-5 months, 9-12 months
Synaptic plasticity: ltd6
Decreased
Description: Decreased recovery of excitatory synaptic connections in pyramidal neurons
Exp Paradigm: Short-term depression of pyramidal neurons
 Whole-cell patch clamp
 Unreported
Neurotransmitter release: catecholamines12
Increased
Description: There is a significant increase in the levels of dopamine in the brains of juvenile fmr1 ko mice
Exp Paradigm: NA
 High-performance liquid chromatography (hplc)
 7-10 weeks
Miniature post synaptic current amplitude: excitatory14
Decreased
Description: Mutants show decreased nmda receptor-mediated epscs in the dg than those in controls.
Exp Paradigm: Nmda receptor-mediated epscs were obtained by holding cells at +40 mv, while 0.05 ms pulses.
 Whole-cell voltage clamp
 Adult
Synaptic plasticity7
Increased
Description: Increased mglur-dependent long term depression in hippocampus
Exp Paradigm: Field recordings in ca1 hippocampal slices
 Field potential recordings
 3 months
Neurotransmitter release: catecholamines10
Decreased
Description: Decreased mpfc dopamine release after intra=thn v1 infusion of lidocaine or kynurenate
Exp Paradigm: Males only
 In vivo amperometry
 Unreported
Synaptic transmission6
Increased
Description: Increased unitary connectivity of neighboring pyramidal neurons
Exp Paradigm: NA
 Whole-cell patch clamp
 Unreported
Epsp-spike relationship14
Decreased
Description: Mutants show decreased slope of nmdar-mediated epsc curve at stimulation intensities ranging between 0.3 and 1.9 ma, compared to controls.
Exp Paradigm: Input-output relationships for the epsc amplitude were measured as a function of afferent fiber stimulus intensity. nmda receptor-mediated epscs were obtained by holding cells at +40 mv, while 0.05 ms pulses.
 Whole-cell voltage clamp
 Adult
Synaptic plasticity9
Increased
Description: Increased maximum transient depression (mtd) in response to dhpg
Exp Paradigm: Extracellular field potentials were recorded in stratum radiatum of ca1 in response to schaffer collateral stimulation from hippocampal slices
 Field potential recordings
 2 months
Neurotransmitter release: catecholamines10
Decreased
Description: Decreased mpfc dopamine release after intra-vta lidocaine or kynurenate infusion
Exp Paradigm: Males only
 In vivo amperometry
 Unreported
Repetitive digging7
Decreased
Description: Decreased number of buried marbles
Exp Paradigm: Marble burying assay
 Marble-burying test
 8-10 weeks
Repetitive digging13
Increased
Description: Fmr1 knockout mice buried more marbles compared to controls.
Exp Paradigm: NA
 Marble-burying test
 4.3 weeks, 6-8 weeks
Seizures9
Increased
Description: Increased seizure response to intense auditory stimuli
Exp Paradigm: Response to intense auditory stimuli (120 db)
 Acoustic startle reflex test
 Unreported
Seizures7
Increased
Description: Increased incidence of audiogenic induced seizures (wild running, seizures, and death)
Exp Paradigm: Audiogenic seizure assay
 Audiogenic seizure test
 P21
Startle response: acoustic stimulus9
Increased
Description: Increased acoustic startle reflex manifesting as whole body startle response
Exp Paradigm: Response to short auditory stimuli of moderate intensity
 Acoustic startle reflex test
 Unreported
Social memory12
Decreased
Description: Fmr1 ko juvenile mice have reduced social memory as they cannot differentiate between a familiar and a stranger mouse
Exp Paradigm: NA
 Three-chamber social approach test
 7-10 weeks
Social interaction4
Decreased
Description: Decreased social interaction demonstrated by reduced active and passive contact time
Exp Paradigm: Direct social interaction task
 Reciprocal social interaction test
 2.5 - 6 months
Social approach5
Increased
Description: Increased social approach evident by increased number of nose contacts with stimulus mouse
Exp Paradigm: Quantification of nose contacts with s1 stimulus mouse after chronic lithium treatment
 Three-chamber social approach test
 3 months
Social interaction5
Increased
Description: Increased social preference indicated by social preference for s2 after treatment
Exp Paradigm: Comparison of interaction with familiar s1 mouse and novel s2 mouse after chronic lithium treatment
 Three-chamber social approach test
 3 months
Social interaction4
Decreased
Description: Decreased social interaction demonstrated by no significant preference for stimulus mouse
Exp Paradigm: Chambered social interaction paradigm; resident-intruder paradigm-reciprocal social interaction test
 Reciprocal social interaction test
 2-6 months
Social approach13
Increased
Description: Fmr1 knockout mice show increased preference for a mouse relative to an object compared to controls.
Exp Paradigm: NA
 Three-chamber social approach test
 4.3 weeks, 6-8 weeks
Social interaction5
Increased
Description: Increased sociability demonstrated by increased time spent in chamber 1
Exp Paradigm: Measurement of preference for chamber with an introduced mouse in social interaction apparatus after chronic lithium treatment
 Three-chamber social approach test
 3 months
Social interaction4
Decreased
Description: Decreased social interaction demonstrated by no significant preference for stimulus mouse
Exp Paradigm: Chambered social interaction paradigm; resident-intruder paradigm- resident-intruder test
 Resident-intruder test
 2-6 months
Social memory5
Decreased
Description: Lack of social preference indicated by no significant preference for novel mouse compared to familiar mouse
Exp Paradigm: Comparison of interaction with familiar s1 mouse and novel s2 mouse
 Three-chamber social approach test
 3 months
Peer-to-peer social attachment17
Decreased
Description: Decrease in peer-peer social conditioned place preference
 Social conditioned place preference test
 3 - 7 weeks
Social interaction5
Decreased
Description: Decreased social interaction indicated by decreased duration of nose contacts with s1 mouse
Exp Paradigm: Quantification of duration of nose contacts with s1 stimulus mouse
 Three-chamber social approach test
 3 months
Social approach15
Decreased
Description: Mutants show decrease in social approach.
Exp Paradigm: NA
 Three-chamber social approach test
 Adult
Hormone levels3
Decreased
Description: Decreased corticosterone levels after acute stress
Exp Paradigm: Corticosterone enzyme immunoassay kit on trunk blood serum after 3-h restraint procedure
 Elisa
 Unreported
Ultrasonic vocalization8
Decreased
Description: Decreased frequency of ultrasonic vocalizations (usv)
Exp Paradigm: Usv produced during mating behavior
 Monitoring ultrasonic vocalizations
 Unreported
Tissue weight9
Increased
Description: Increased testis weight
Exp Paradigm: General observations
 General observations
 5-17 weeks
Size/growth4
Increased
Description: Increased body weight
Exp Paradigm: General observations
 General observations
 2.5 - 6 months
Anxiety11
Decreased
Description: Fmr1 ko mice spend more time in the light chamber and have more gate crossings showing reduced anxiety
Exp Paradigm: The dark chamber was not illuminated and the light chamber was illuminated with a fluorescent light. mice were placed in the dark chamber for 2 min. the divider separating the two chambers was then removed and the mice were allowed to freely investigate both chambers for 10 min. the time spent in the light chamber and the number of gate crossings in the light-dark box were recorded
 Light-dark exploration test
 P29
Anxiety3
Decreased
Description: Decreased anxiety levels in elevated plus maze and also demonstrated by increased distance travelled in center of open field
Exp Paradigm: Elevated plus maze test-elevated plus maze test
 Elevated plus maze test
 2-4 months
Anxiety12
Increased
Description: Fmr1 ko mice have increased anxiety tested in the open field, tested by counting the number of faecal boli
Exp Paradigm: NA
 Open field test
 7-10 weeks
Anxiety3
Decreased
Description: Decreased anxiety levels in elevated plus maze and also demonstrated by increased distance travelled in center of open field
Exp Paradigm: Elevated plus maze test- open field test
 Open field test
 2-4 months
Anxiety5
Increased
Description: Increased anxiety demonstrated by increased time rearing and digging during social preference period
Exp Paradigm: Observation during social preference
 Three-chamber social approach test
 3 months
Anxiety13
Increased
Description: Fmr1 knockout mice show increased preference for the outer zone versus the inner zone of the open field compared to controls.
Exp Paradigm: NA
 Open field test
 5 weeks
Anxiety5
Decreased
Description: Decreased anxiety
Exp Paradigm: Observation during social preference
 Three-chamber social approach test
 3 months
Anxiety11
Decreased
Description: Fmr1 ko mice spend more time in the open arms in the elevated plus maze showing reduced anxiety
Exp Paradigm: Time spent in the open arms of the plus maze was recorded. mice were placed in the center of the maze and allowed to freely explore the covered and the open arms
 Elevated plus maze test
 P29
Anxiety7
Decreased
Description: Decreased anxiety measured by increased time spent and distance traveled in the center of chamber
Exp Paradigm: Open field test for both male and female
 Open field test
 Unreported
Object recognition memory13
Decreased
Description: Fmr1 knockout mice show reduced discrimination index between a novel and familiar object 1 day after initial exposure, compared to controls.
Exp Paradigm: NA
 Novel object recognition test
 4-8 weeks
Cued or contextual fear conditioning11
Decreased
Description: Fmr1 ko mice show reduced (but insignificant) freezing in the contextual fear conditioning paradigm comapred to wt controls
Exp Paradigm: The standard fear conditioning training consisted of a 3 min exposure of mice to conditioning box (context) followed by a foot shock, after a preceding tone (30 s, 3khz, 75db). the memory test is performed after 24 h by re exposing the animals for 5 min to the conditining context and 1 h later to a novel context for 3 min followed by a tone( 3 min, 3 khz, 75 db)
 Fear conditioning test
 P29
Spatial reference memory14
Decreased
Description: Mutants spent less time exploring compared to controls, indicating impairment in dg-dependent pattern separation learning.
Exp Paradigm: NA
 Object-place recognition test
 Adult
Eye blink conditioning11
Decreased
Description: Percentage of eye blink conditioned respones was significantly reduced.
Exp Paradigm: NA
 Eyeblink conditioning
 Unreported
Reward reinforced choice behavior11
Decreased
Description: Fmr1 ko mice show reduced learning in the conditional cue dependent choice task, wt mice progressively learned the task
Exp Paradigm: Y maze learning test was carried out using an elevated y maze, one start arma nd two goal arms. the food well located at the end of each goal arm was filled with sucrose sweetened non fat dairy milk as a reward. after 18 h food fasting with no restriction on water access, mice were first habituated to y maze and milk reward. mice were then trained and tested on a conditional learning task using interchangeable floor inserts, either plain or white or black wire mesh, covering the whole of the start arm, this was the conditional cue. the presence of the plain white insert indicated the presence of milk reward in the right goal arm and the black wire mesh indicated the milk reward was present in the left arm. mice received 14 training sessions consisting of 10
 Y-maze test
 P29
Cued or contextual fear conditioning: memory of cue9
Decreased
Description: Decreased cued fear conditioning indicated by reduced latency to enter the dark compartment
Exp Paradigm: Inhibitory avoidance paradigm
 Passive avoidance test
 Unreported
Object recognition memory14
Decreased
Description: Mutants show decrease in ability to recognize a novel object compared to controls.
Exp Paradigm: NA
 Novel object recognition test
 Adult
Cued or contextual fear conditioning11
Decreased
Description: Fmr1 ko mice show significantly reduced freezing in the more demanding associative learning in trace fear conditioning paradigm comapred to wt controls
Exp Paradigm: Trace fear conditioning traning consisted of a 15-sec white noise conditioned stimulus (cs) and a 0.5 s scrambled foot shock (us). mice were acclimated for 60 sec and then presented with seven cs-trace-us intertrial interval trials ( trace, 30 sex, iti, 210 sec). one day after training, mice were acclimated for 60 sec followed by 7 cs iti trials ( iti, 30 sec) in a novel chamber to test for trace fear memory.
 Fear conditioning test
 P29
Protein expression level evidence4
Decreased
Description: Decreased expression of nlgn1 in hippocampus and cerebellum, but not cortex
Exp Paradigm: Protein expression
 Immunohistochemistry
 2.5 - 6 months
Protein-dna complex assembly13
Increased
Description: Fmr1 knockout mice show increased protein occupancy at the brd4 target genes compared to controls.
Exp Paradigm: NA
 Quantitative pcr (qrt-pcr)
 2.1 weeks
Gene expression1
Increased
Description: Abnormal differential gene expression; 81 cdnas were overexpressed
Exp Paradigm: Differential gene expression
 Quantitative pcr (qrt-pcr)
 9-13 weeks
Protein localization: synapse14
Decreased
Description: Mutants show a decrease in the levels of psd-95 (dlg4) in the synaptoneurosome fraction of the dentate gyrus, compared to controls, but not in the whole tissue lysate of the dentate gyrus.
Exp Paradigm: NA
 Western blot
 Adult
Signaling9
Decreased
Description: Abnormal intracellular signaling in cerebral cortex indicated by increased erk & mtor phosphorylation
Exp Paradigm: Intracellular signaling
 Western blot
 Unreported
Protein expression level evidence1
Decreased
Description: Decreased expression of gabaa receptor subunit in neocortex and hippocampus. no change in cerebellum, caudate putamen, thalamus, and bulbus olfactorius
Exp Paradigm: Gabaa receptor subunit gene expression
 Immunohistochemistry
 10 weeks
Protein phosphorylation14
Increased
Description: Mutants show increase in akt phosphorylation (pakt/akt levels) in the synaptoneurosomal fraction of the dentate gyrus but not the whole lysate of the dentate gyrus or the whole lysate of the hippocampal ca1 region, compared to controls. mutants show increase in erk phosphorylation (perk/erk levels) in the synaptoneurosomal fraction of the dentate gyrus but not the whole lysate of the dentate gyrus or the whole lysate of the hippocampal ca1 region, compared to controls.
Exp Paradigm: NA
 Western blot
 Adult
Gene expression1
Decreased
Description: Abnormal differential gene expression; 143 cdnas underexpressed
Exp Paradigm: Differential gene expression
 Differential display analysis of hippocampus
 9-13 weeks
Protein expression level evidence7
Increased
Description: Increased levels of amyloid beta and amyloid beta precursor protein levels
Exp Paradigm: Amyloid beta protein levels
 Western blot
 1 month
Regulation of translation9
Increased
Description: Increased rate of protein synthesis
Exp Paradigm: Protein synthesis levels
 Metabolic labeling of proteins
 Unreported
Gene expression13
Increased
Description: Fmr1 knockout mice show increased transcript levels for nr4a1, shank2, arc and gria1 in the cerebral cortex compared to controls.
Exp Paradigm: NA
 Quantitative pcr (qrt-pcr)
 Not specified
Protein phosphorylation13
Increased
Description: Fmr1 knockout mice show increased phosphorylation of brd4 indicating that increased levels of brd4 in fmr1 mutants correlates with increased levels of activated brd4.
Exp Paradigm: NA
 Western blot
 2.1 weeks
Transcriptome diversity17
Decreased
Description: Decreased mitochondrial density measurements consistent with the identity of parvocellular ot neurons
 Flow cytometric analysis
 3 - 7 weeks
Differential gene expression17
Abnormal
Description: Abnormal gene expression profile indicating the dysfunction of parvocellular ot neurons; asd risk and fmrp target genes are enriched in parvocellular ot neurons
 RNA sequencing
 3 - 7 weeks
Protein expression level evidence13
Increased
Description: Fmr1 knockout mice show increased expression of fmrp target proteins, including brd4, mll1, and p300, compared to controls.
Exp Paradigm: NA
 Western blot
 2.1 weeks
Regulation of gene expression13
Abnormal
Description: Fmr1 knockout mice show widespread misregulation of transcription with more genes increased than decreased compared to controls. changes in gene expression were highly correlated with changes in h3k4me3 and h3k27ac levels in fmr1 knockout mice. upregulated genes were typically high expressers and included synaptic proteins and receptor proteins. downregulated genes in fmr1 mutants included transcriptional regulators. genes misregulated in fmr1 mutant mice show a significant overlap with asd genes.
Exp Paradigm: NA
 Rna sequencing
 2.1 weeks
Gene expression1
Abnormal
Description: Abnormal gene differential expression of 8 cdnas
Exp Paradigm: Gene expression
 Semi-quantitative pcr (qrt-pcr)
 10-11 weeks
Protein modification process11
Increased
Description: Fmr1 ko mice have elevated basal levels of ras-gtpduring sleeping and reduced ranges of ras activation between sleeping and awake states comapred to wt mice. both wt and fmr1 ko mice had increased ras-gtpin awake states
Exp Paradigm: Protein modification
 Western blot
 P14, p29
Signaling11
Decreased
Description: There is decreased signal transduction between ras gtpto pi3/pkb proteins in fmr1 ko mice, as there is decreased phosphorylated pkb in the awake state in the ko mice, whereas there is increased phosphorylated pkb in wt mice in the awake state.
Exp Paradigm: Signaling
 Western blot
 P14, p29
Chromatin modification: histone modification: open chromatin13
Increased
Description: Fmr1 knockout mice show increased histone modifications associated with active chromatin compared to controls, including h3 lysine 4 trimethylation (h3k4me3), h3 lysine 27 acetylation (h3k27ac), and h4 lysine 8 and 16 acetylation (h4k8ac and h4k16ac). fmr1 knockout mice show increased h3k4me3 at nr4a1 and shank3 and throughout the genome with increased abundance at transcription start sites, and increased h3k27ac in neurons, compared to controls.
Exp Paradigm: NA
 Chromatin immunoprecipitation sequencing (chip-seq)
 2.1 weeks
Ultrasonic vocalization11
 No change
 Monitoring ultrasonic vocalizations
 Unreported
Mortality/lethality4
 No change
 General observations
 2.5 - 6 months
Anxiety13
 No change
 Open field test
 6-8 weeks
Anxiety14
 No change
 Open field test
 Adult
Depression14
 No change
 Tail suspension test
 Adult
Depression14
 No change
 Forced swim test
 Adult
Exploratory activity: habituation14
 No change
 Object-place recognition test
 Adult
Object recognition memory4
 No change
 Novel object recognition test
 2.5 - 6 months
Procedural learning14
 No change
 Novel object recognition test
 Adult
Reward reinforced choice behavior: cocaine17
 No change
 Cocaine conditioned place preference test
 3 - 7 weeks
Spatial learning4
 No change
 Morris water maze test
 2.5 - 6 months
Spatial reference memory3
 No change
 Plus-shaped water maze test
 2-4 months
Spatial reference memory3
 No change
 Morris water maze test
 2-4 months
Chromatin modification13
 No change
 Chromatin immunoprecipitation sequencing (chip-seq)
 2.1 weeks
Protein expression level evidence4
 No change
 Immunohistochemistry
 2.5 - 6 months
Protein expression: in situ protein expression1
 No change
 Immunohistochemistry
 4 months
Protein expression: in situ protein expression1
 No change
 Immunohistochemistry
 4 months
Regulation of translation1
 No change
 Semi-quantitative pcr (qrt-pcr)
 Unreported
Regulation of translation1
 No change
 Quantitative pcr (qrt-pcr)
 Unreported
Transcriptome diversity1
 No change
 Quantitative pcr (qrt-pcr)
 Unreported
Transcriptome diversity1
 No change
 Gene expression microarray
 Unreported
General locomotor activity3
 No change
 Open field test
 Unreported
General locomotor activity17
 No change
 Conditioned place preference test
 3 - 7 weeks
General locomotor activity7
 No change
 Open field test
 Unreported
General locomotor activity: ambulatory activity13
 No change
 Open field test
 5 weeks
Brain development3
 No change
 Immunohistochemistry
 Unreported
Microglial morphology18
 No change
 Immunohistochemistry
 2 weeks
Microglial number18
 No change
 Immunohistochemistry
 2 weeks
Epsp-spike relationship14
 No change
 Whole-cell voltage clamp
 Adult
Miniature post synaptic current amplitude: excitatory14
 No change
 Whole-cell voltage clamp
 Adult
Neurotransmitter release: catecholamines10
 No change
 In vivo amperometry
 Unreported
Presynaptic function: paired-pulse facilitation7
 No change
 Paired-pulse ratio
 Unreported
Synaptic plasticity: ltd6
 No change
 Whole-cell patch clamp
 4-5 weeks
Synaptic transmission6
 No change
 Whole-cell patch clamp
 4-5 weeks
Hormone levels3
 No change
 Elisa
 Unreported
Repetitive digging12
 No change
 Marble-burying test
 4-6 weeks
Aggression4
 No change
 Resident-intruder test
 2.5 - 6 months
Filial social attachment17
 No change
 Alloparent conditioned place preference test
 3 - 7 weeks
Mating behavior8
 No change
 Reciprocal social interaction test
 Unreported
Self grooming: social context5
 No change
 Three-chamber social approach test
 3 months
Social approach12
 No change
 Three-chamber social approach test
 7-10 weeks
Social approach5
 No change
 Three-chamber social approach test
 3 months
Social approach5
 No change
 Three-chamber social approach test
 3 months
Social interaction5
 No change
 Three-chamber social approach test
 3 months
Social interaction5
 No change
 Three-chamber social approach test
 3 months
Social interaction5
 No change
 Three-chamber social approach test
 3 months
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_3_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Neurotransporter expression2
Decreased
Description: Fmr1 ko mice show reduced expression of kcc2 chloride exporter channels in the hippocampi compared to wt littermates.
Exp Paradigm: NA
 Immunocytochemistry
 P15
Spontaneous post synaptic events2
Increased
Description: Hippocampal slices of newborn and young fmr1 ko pups showed bursting activity and a four-fold increase in spontaneous excitatory postsynaptic currents
Exp Paradigm: NA
 Whole-cell patch clamp
 P0, p15
Population spikes2
Increased
Description: Brain slices extracted from early postnatal fmr1 ko pups show increased field potential recordings after treatment with gabaa r agonist: isoguvacine, unlike slices from wt littermates
Exp Paradigm: Field potential recordings of slices treated with isoguvacine
 Field potential recordings
 P15
Driving force of ion channel or receptor2
Increased
Description: Fmr1 ko mice show a continued elevated driving force of gabaa receptor (chloride ion channel) in fetal neurons from embryonic day 20- 21 through post natal day 15 and 30, unlike wt littermates who had elevated driving force only during the embryonic stages and showed a reduction in the driving force in early post natal stages.
Exp Paradigm: NA
 Cell-attached patch clamp
 E20-e21, p15, p30
Action potential property: firing rate2
Increased
Description: Neurons extracted from newborn fmr1 ko pups show increased spike ( action potential) frequencies when treated with the gabaa r agonist: isoguvacine, unlike wt littermate neurons, that did not show an increased spike frequency following the treatment.
Exp Paradigm: Cell attached recordings of slices treated with isoguvacine
 Cell-attached patch clamp
 P0
Ultrasonic vocalization2
Decreased
Description: Fmr1ko pups had a higher probability of emitting downward and chevron calls than control pups.
Exp Paradigm: NA
 Monitoring ultrasonic vocalizations
 P8
Reproductive system development1
Decreased
Description: Increased testis weights or macroorchidism indicates deficit in the development of reproductory organs
Exp Paradigm: NA
 Measurement of tissue weight
 Unreported
Targeted expression1
Decreased
Description: Drastically reduced levels of fmr1 transcripts in brain and of the fmrp
Exp Paradigm: M_fmr1 gene expression- quantitative pcr (qrt-pcr): brain
 Quantitative pcr (qrt-pcr)
 Unreported
Targeted expression1
Decreased
Description: Drastically reduced levels of fmr1 transcripts in brain and of the fmrp
Exp Paradigm: M_fmr1 gene expression-immunocytochemistry: brain or testis by using anti-fmrpantibody
 Immunocytochemistry
 Unreported
Targeted expression1
Decreased
Description: Drastically reduced levels of fmr1 transcripts in brain and of the fmrp
Exp Paradigm: M_fmr1 gene expression- western blot: brain lysate
 Western blot
 Unreported
General characteristics1
 No change
 General observations
 Unreported
General characteristics1
 No change
 General observations
 Unreported
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_4_CKO_HM_PURKINJEN

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Reproductive system development1
Decreased
Description: Increased testis weights or macroorchidism indicates deficit in the development of reproductory organs
Exp Paradigm: General observations
 General observations
 Unreported
Targeted expression1
Decreased
Description: Absence of fmrpin purkinje cells but positive staining in cells of neuronal and glial lineage
Exp Paradigm: Fmrpexpression
 Immunohistochemistry
 Unreported
General characteristics1
 No change
 General observations
 Unreported
 Not Reported: Circadian sleep/wake cycle, Communications, Emotion, Immune response, Learning & memory, Maternal behavior, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_9_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Brain cytoarchitecture1
Increased
Description: Increased soma area of parvalbumin (pv) neurons in thalamocortical slices
Exp Paradigm: NA
 Cell size measurement
 12 months
Neuronal number: interneurons1
Decreased
Description: Decreaed number of parvalbumin positive neurons in thalamocortical sections
Exp Paradigm: Pv
 Immunohistochemistry
 12 months
Brain morphology1
Increased
Description: Increased number of parvalbumin (pv) neurons in layers v and vi in somatosensory cortex
Exp Paradigm: Double immunohistochemistry and dapi staining of the somatosensory cortex using anti-pv antibody
 Immunohistochemistry
 12 months
Brain morphology1
Decreased
Description: Decreased number of parvalbumin (pv) neurons in layers ii/iii and iv in somatosensory cortex
Exp Paradigm: Double immunohistochemistry and dapi staining of the somatosensory cortex using anti-pv antibody
 Immunohistochemistry
 12 months
Protein expression level evidence1
Increased
Description: Increased expression of trkb in cell bodies of parvalbumin expressing interneurons
Exp Paradigm: Trkb protein expression
 Immunohistochemistry
 12 months
Protein expression level evidence1
Decreased
Description: Decreased trkb protein expression as demonstrated by decreased number of puncta oriented perpendicularly to pia surface and reduction in total number of trkb positive puncta
Exp Paradigm: Trkb protein expression
 Immunohistochemistry
 12 months
Brain morphology1
 No change
 Immunohistochemistry
 12 months
Brain morphology1
 No change
 Immunohistochemistry
 12 months
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Motor phenotype, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_2_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Spontaneous movement5
Increased
Description: Increased spontaneous movement
Exp Paradigm: Number of crossing through three infrared beams in an empty cage
 Home cage behavior
 Unreported
General locomotor activity2
Increased
Description: Increased spontaenous locomotor activity demonstrated by greater distance traveled and greater average velocity
Exp Paradigm: Open field test
 Open field test
 3 months
Miniature post synaptic currents: excitatory3
Increased
Description: Increased excitatory postsynaptic current amplitude after 8-oh-dpat administration
Exp Paradigm: Whole cell recordings of hippocampal cultures
 Whole-cell patch clamp
 P0-p1
Miniature post synaptic currents: excitatory3
Decreased
Description: Decreased excitatory postsynaptic current amplitude after application of dhpg indicative of enhanced mglur-ltd
Exp Paradigm: Whole cell recordings of hippocampal cultures
 Whole-cell patch clamp
 P0-p1
Synaptic transmission1
Decreased
Description: Decreased glycine-induced long term potentiation in hippocampal slices
Exp Paradigm: NA
 Field potential recordings
 Unreported
Touch4
Increased
Description: Fmr1 kos show an increased response to just air puff indicating aberrant sensitivity or hypersensitivity
Exp Paradigm: NA
 Response to air puff
 6-8 weeks
Sensorimotor gating: tactile cue4
Decreased
Description: Tactile prepulse inhibition responses are enhanced in fmr1 ko mice, as opposed to control littermates that display reduced magnitude of acoustic startle response when they receive an air puff prepulse
Exp Paradigm: NA
 Prepulse inhibition
 6-8 weeks
Tactile memory4
Decreased
Description: Fmr1 kos have reduced discrimination and memory for objects differing in texture (rough or smooth) and do not preferentially interact with a novel textured-object over a familiar one
Exp Paradigm: NA
 Textured novel object recognition test (t-nort)
 6-8 weeks
Sensorimotor gating2
Increased
Description: Increased sensorimotor gating measured by prepulse inhibition with all prepulses, but more pronounced with lower decibel
Exp Paradigm: Prepulse inhibition test
 Prepulse inhibition
 3 months
Startle response: acoustic stimulus2
Decreased
Description: Decreased acoustic startle reflex
Exp Paradigm: Acoustic startle reflex after intraperitoneal administration of thip(10 mg/kg)
 Prepulse inhibition
 3 months
Startle response: acoustic stimulus2
Decreased
Description: Decreased acoustic startle reflex
Exp Paradigm: Acoustic startle reflex
 Prepulse inhibition
 3 months
Social interaction5
Increased
Description: More exploratory activity
Exp Paradigm: Movement in and between two compartments (one lit and one dark) of a box
 Light-dark exploration test
 Unreported
Reproductive system development5
Decreased
Description: Macroorchidism indicates deficits in reproductive system development
Exp Paradigm: General observation; light microscopic examination-general observations
 General observations
 5-7 weeks, 2.5 months; 3.5 months; 5.5 months
Reproductive system development5
Decreased
Description: Macroorchidism indicates deficits in reproductive system development
Exp Paradigm: General observation; light microscopic examination- histology: testis
 Histology
 5-7 weeks, 2.5 months; 3.5 months; 5.5 months
Cued or contextual fear conditioning: memory of cue2
Decreased
Description: Decreased cued conditioning learning measured as freezing patterms
Exp Paradigm: Cued fear conditioning test
 Fear conditioning test
 3 months
Spatial learning5
Decreased
Description: Decreased spatial learning
Exp Paradigm: Hidden platform condition of morris water maze task
 Morris water maze test
 Unreported
Object recognition memory: long-term recall4
Decreased
Description: Fmr1 kosmice have reduced preference for novel object when the retention period (or interval) is extended to 1 hr from 5 min, whereas wt mice still prefer the novel object
Exp Paradigm: NA
 Novel object recognition test
 6-8 weeks
Cued or contextual fear conditioning: memory of cue2
Decreased
Description: Decreased cued conditioning learning measured as freezing patterms
Exp Paradigm: Cued fear conditioning test after intraperitoneal administration of thip(10 mg/kg)
 Fear conditioning test
 3 months
Reproductive system development5
 No change
 General observations
 Unreported
Anxiety2
 No change
 Open field test
 3 months
Exploratory activity4
 No change
 Textured novel object recognition test (t-nort)
 6-8 weeks
Cued or contextual fear conditioning: memory of context2
 No change
 Fear conditioning test
 3 months
Cued or contextual fear conditioning: memory of cue5
 No change
 Passive avoidance test
 Unreported
Object recognition memory4
 No change
 Novel object recognition test
 6-8 weeks
Spatial learning5
 No change
 Morris water maze test
 Unreported
General locomotor activity2
 No change
 Open field test
 3 months
Brain size5
 No change
 Macroscopic analysis
 2 months
Sensorimotor gating4
 No change
 Prepulse inhibition
 6-8 weeks
Sensorimotor gating2
 No change
 Prepulse inhibition
 3 months
Startle response: acoustic stimulus4
 No change
 Acoustic startle reflex test
 6-8 weeks
Social interaction5
 No change
 Reciprocal social interaction test
 Unreported
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_6_KI_HM_I304N

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
General locomotor activity1
Increased
Description: Increased general locomotor activity
Exp Paradigm: Open field test for activity
 Open field test
 Unreported
Repetitive digging1
Increased
Description: Increase repetitive behavior as measured by marble burying
Exp Paradigm: Marble-burying test indicative of repetitive behavior
 Marble-burying test
 Unreported
Pain or nociception1
Decreased
Description: Decreased sensitiity to pain
Exp Paradigm: Hot plate test for a measure of pain sensitivity
 Hot plate test
 Unreported
Reproductive system development1
Increased
Description: Increased macroorchidism
Exp Paradigm: General observations
 General observations
 Unreported
Anxiety1
Decreased
Description: Decreased anxiety
Exp Paradigm: Anxiety measured in open field test & light/dark box-open field test
 Open field test
 Unreported
Anxiety1
Decreased
Description: Decreased anxiety
Exp Paradigm: Anxiety measured in open field test & light/dark box- light-dark exploration test
 Light-dark exploration test
 Unreported
General characteristics1
 No change
 General observations
 Unreported
Size/growth1
 No change
 General observations
 Unreported
Hyperactivity1
 No change
 Open field test
 Unreported
Sensorimotor gating1
 No change
 Prepulse inhibition
 Unreported
 Not Reported: Circadian sleep/wake cycle, Communications, Immune response, Learning & memory, Maternal behavior, Molecular profile, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Seizure, Social behavior

M_FMR1_11_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
General locomotor activity2
Increased
Description: Increase in time spent walking and running
 Observation of repetitive behavior
 2 months
Dendritic architecture: spine morphology2
Decreased
Description: Decrease in the number of stubby and mushroom type mature neurons
 Electron microscopy
 2 months
Synaptic morphology2
Decreased
Description: Smaller synapses within the ca1 region hippocampus
 Electron microscopy
 2 months
Dendritic architecture: spine density2
Abnormal
Description: Increase in immature dendritic spine density; decrease in mature dendritic spine density
 Electron microscopy
 2 months
Mitochondrial number2
Decreased
Description: Decrease in the total area covered by mitochondria in synapses; no change in mitochondrial area per synapse area, indicating that mitochondrial size was scaled to the smaller synapse size
 Electron microscopy
 2 months
Mitochondrial matrix morphology2
Increased
Description: Increase in matrix density of mitochondria
 Electron microscopy
 2 months
Synaptic morphology: active zone2
Decreased
Description: Smaller pools of presynaptic vesicle
 Electron microscopy
 2 months
Mitochondrial membrane potential2
Increased
Description: Increased multi-conductance, voltage-dependent channel activity in brain smvs indicating that lack of sequestration of h+ ions in the acma assay was due to leaky smv membranes
 Whole-cell patch clamp
 2 months
Mitochondrial ATP synthesis coupled electron transport2
Decreased
Description: Submitochondrial vesicles failed to sequester h+ ions in response to atp addition, indicating either a failure of the enzyme to translocate h+ or an h+ leak in the submitochondrial vesicle membranes; slight decrease in atp levels
 9-amino-6-chloro-2-methoxyacridine (ACMA) assay
 2 months
Self grooming2
Increased
Description: Increase in self grooming duration and attempts
 Grooming behavior assessments
 2 months
Stereotypy: chewing behavior2
Increased
Description: Increased nest shredding weight, indicating increase in repetitive chewing
 Observation of repetitive behavior
 2 months
Mitochondrial proton-transporting ATP synthase complex, catalytic sector F(1)
Increased
Description: Increased levels of atp synthase b-subunit (f1) mrna, indicating although loss of fmrp may lead to enhanced transcription of both b and c-subunit mrnas, in contrast only b
 
 
Protein phosphorylation1
Increased
Description: Increased mtor phosphorylation at ser2448 in forebrain, whole cell lysates, and isolated postynaptic densities of hippocampus
Exp Paradigm: Mtor phosphorylation
 Western blot
 4-6 weeks, 6-8 months
Mitochondrial proton-transporting ATP synthase complex, coupling factor F(o)2
Increased
Description: Increased levels of free atp synthase c-subunit (fo)
 Native non-denaturing polyacrylamide gel electrophoresis
 2 months
Regulation of translation2
Increased
Description: Increased incorporation of puromycin
 Puromycin incorporation assay
 2 months
Glycolysis2
Increased
Description: Increase in glycolytic enzymes including hexokinase ii, pyruvate kinase m2 variant and lactate dehydrogenase measured by labeling newly synthesized proteins with puromycin and immunoprecipitating with an anti-puromycin antibody
 Liquid chromatography-mass spectrometry (LC-MS)
 2 months
Protein binding2
Decreased
Description: Decreased binding of fmrp binding to the beta subunit of atp synthase mrna in neuronal synaptosomal fraction
 Co-immunoprecipitation
 2 months
Mitochondrial proton-transporting ATP synthase complex, coupling factor F(o)2
Increased
Description: Increased levels of atp synthase c-subunit (fo) protein
 Western blot
 2 months
Regulation of translation2
Increased
Description: Increase in the number of actively translating ribosomal assemblies (rosettes) in ca1 neurons
 Electron microscopy
 2 months
Enzyme activity1
Increased
Description: Increased mtor kinase activity demonstrated by increased association of mtor with raptor in hippocampal slices
Exp Paradigm: Mtor kinase activity
 Western blot
 4-6 weeks
Neuronal activity dependent translation2
Decreased
Description: Disruption of synaptic stimulation-induced changes in protein synthesis in synaptosomes ; decrease in synaptic-stimulation induced increase in atp synthase b-subunit (f1) protein synthesis compared with controls
 Western blot
 2 months
Mitochondrial proton-transporting ATP synthase complex, catalytic sector F(1)2
Increased
Description: Increased levels of atp synthase b-subunit (f1) protein
 Western blot
 2 months
Regulation of gene expression1
Increased
Description: Increased phosophorylation of 4e-bpand association of eif4g with eif4e in hippocampal slices
Exp Paradigm: Eif4f transcription initiation complex formation
 Western blot
 4-6 weeks
Neuronal activity dependent phosphorylation2
Decreased
Description: Disruption of synaptic stimulation-induced changes in ef2 phosphorylation in synaptosomes
 Western blot
 2 months
Tricarboxylic acid cycle2
Increased
Description: Increase in enzymes of tricarboxylic acid cycle and nad+/nadh metabolism, including enzymes of the malate/aspartate shunt and isocitrate dehydrogenase measured by labeling newly synthesized proteins with puromycin and immunoprecipitating with an anti-puromycin antibody
 Liquid chromatography-mass spectrometry (LC-MS)
 2 months
Enzyme activity1
 No change
 Western blot
 4-6 weeks
Mitochondrial proton-transporting ATP synthase complex assembly2
 No change
 Native non-denaturing polyacrylamide gel electrophoresis
 2 months
Protein expression level evidence1
 No change
 Western blot
 4-6 weeks; 6-8 months
Protein phosphorylation1
 No change
 Western blot
 4-6 weeks
Mitochondrial crista morphology2
 No change
 Electron microscopy
 2 months
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_5_KI_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
General locomotor activity1
Increased
Description: Increased horizontal distance traveled indicated increased general locomotor activity i.e. hyperactivity
Exp Paradigm: Males only
 Open field test
 7-9 weeks
Dendritic architecture: spine density1
Increased
Description: Increased dendritic spine density in neurons in medial prefrontal cortex, dorsal hippocampus, basal lateral amygdala
Exp Paradigm: Males only
 Golgi-cox staining
 17 weeks
Dendritic architecture: dendritic tree complexity1
Decreased
Description: Decreased arborization of dendrites in layer iii pyramidal neurons, ca3 pyramidal cells, and pyramidal and stellate cells in basal lateral amygdala
Exp Paradigm: Males only
 Golgi-cox staining
 17 weeks
Reproductive system development1
Decreased
Description: Deficit in developmental trajectory demonstrated by increased testicular weights, which is not normal in the development of reproductive organs
Exp Paradigm: NA
 Measurement of tissue weight
 NA
Anxiety1
Decreased
Description: Decreased anxiety indicated by more time spent in open quadrants in epm and indicated by fraction of distance traveled in margins of field in open field test
Exp Paradigm: Elevated zero maze test-elevated zero maze test
 Elevated zero maze test
 10-13 weeks
Anxiety1
Decreased
Description: Decreased anxiety indicated by more time spent in open quadrants in epm and indicated by fraction of distance traveled in margins of field in open field test
Exp Paradigm: Elevated zero maze test- open field test
 Open field test
 10-13 weeks
Cued or contextual fear conditioning: passive avoidance1
Decreased
Description: Decreased latency to enter the dark compartment 24hours after training in the passive avoidance task, compared to wild type
Exp Paradigm: Passive avoidance task
 Passive avoidance test
 13-16 weeks
Protein expression level evidence1
Decreased
Description: Decreased levels of fmrpprotein throughout brain
Exp Paradigm: Fmrpprotein expression
 Western blot
 3 months
Gene expression1
Increased
Description: Increased levels of fmr1 mrna throught the brain
Exp Paradigm: M_fmr1 mrna expression
 Quantitative pcr (qrt-pcr)
 3 months
Regulation of translation1
Increased
Description: Increased rate of cerebral protein synthesis (rcps) as measured across various brain regions including dorsal/ventral hippocampus and cortical areas
Exp Paradigm: Cerebral protein synthesis rate
 Autoradiographic analysis
 17 weeks
General characteristics1
 No change
 General observations
 Unreported
Size/growth1
 No change
 General observations
 Unreported
Motor coordination and balance1
 No change
 Accelerating rotarod test
 Unreported
Social approach1
 No change
 Three-chamber social approach test
 8-10 weeks
Social memory1
 No change
 Three-chamber social approach test
 8-10 weeks
 Not Reported: Circadian sleep/wake cycle, Communications, Immune response, Maternal behavior, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory

M_FMR1_8_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Motor coordination and balance1
Decreased
Description: Decreased motor coordination
Exp Paradigm: Males only
 Accelerating rotarod test
 Unreported
Dendritic architecture: spine density1
Abnormal
Description: Abnormal spine morphology of pyramidal neurons in hippocampal area ca1 with higher fraction of fliopodia-like and thin spines compared to stubby and mushroom spines
Exp Paradigm: Males only
 Golgi-cox staining
 3-4 months
Dendritic architecture: spine density1
Increased
Description: Increased spine density in pyramidal neurons in hippocampal area ca1
Exp Paradigm: Males only
 Golgi-cox staining
 3-4 months
Synaptic plasticity: ltd1
Increased
Description: Increased induction of mglur long term depression in hippocampus
Exp Paradigm: Males only
 Whole-cell patch clamp
 3-5 weeks
Stereotypy1
Increased
Description: Increased repetitive behavior measured through number of marbles buried
Exp Paradigm: Males only
 Marble-burying test
 Unreported
Social memory1
Decreased
Description: Reduced social memory indicated by failure to distinguish familiar from novel mice
Exp Paradigm: Males only
 Three-chamber social approach test
 Unreported
Social interaction1
Increased
Description: Increased exploratory activity
Exp Paradigm: Males only
 Open field test
 Unreported
Size/growth1
Increased
Description: Increased rate of weight gain
Exp Paradigm: Males only
 General observations
 6 weeks
Reproductive system development1
Decreased
Description: Deficit in developmental trajectory demonstrated by increased testicular weights, which is not normal in the development of reproductive organs
Exp Paradigm: Males only
 General observations
 3-4 months
Object recognition memory1
Decreased
Description: Decreased novel object recognition memory
Exp Paradigm: Males only
 Novel object recognition test
 Unreported
Spatial working memory1
Decreased
Description: Decreased spatial working memory as assayed through reversal learning
Exp Paradigm: Males only
 Water y-maze test
 Unreported
Protein modification process1
Increased
Description: Increased levels of phosphorylated s6 in hippocampal area ca1
Exp Paradigm: Males only
 Immunohistochemistry
 8-10 weeks
Protein expression level evidence1
Increased
Description: Increased levels of expression of synaptic proteins psd-95, camkiia, shank3; translation factors eif4g, eef2
Exp Paradigm: Males only
 Western blot
 Unreported
Regulation of translation1
Increased
Description: Increased protein synthesis levels in hippocampal slices measured through levels of puromycin labeling
Exp Paradigm: Males only
 Surface sensing of translation (sunset)
 Unreported
Protein phosphorylation1
Increased
Description: Increased phosphorylation of key translational control molecules - s6 at 240/244 and 235/36 phosphorylation sites, eif4b, mtor, erk in whole hippocampal lysates
Exp Paradigm: Males only
 Western blot
 Unreported
Spatial working memory1
 No change
 Water y-maze test
 Unreported
Protein expression level evidence1
 No change
 Western blot
 Unreported
 Not Reported: Circadian sleep/wake cycle, Communications, Emotion, Immune response, Maternal behavior, Physiological parameters, Seizure, Sensory

M_FMR1_7_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
General locomotor activity3
Increased
Description: Increased locomotor activity indicated by more line crosses
Exp Paradigm: Open field test
 Open field test
 4, 8 weeks
General locomotor activity2
Increased
Description: Increased locomotor activity indicated by greater distance traveled, more distinct horizontal movement, and more time spent moving
Exp Paradigm: Open field test
 Open field test
 10-17 weeks
General locomotor activity3
Increased
Description: Increased locomotor activity indicated by more total arm entries
Exp Paradigm: Elevated plus maze test
 Elevated plus maze test
 4, 8 weeks
Dendritic architecture: spine density2
Increased
Description: Increased mean density of apical dendritic spines in segment 3 without changes in segments 1-2 and 5-10
Exp Paradigm: Golgi staining procedure of pyramidal cells in cortical layers ii/iii of temporal lobe
 Golgi-cox staining
 11 weeks
Action potential property: firing rate5
Decreased
Description: Mutants show reduced spontaneous spiking of l2/3 fast spiking units but show no change in spontaneous spiking of regular spiking units in the vrc compared with controls.
Exp Paradigm: Ventra retrosplenial cortex
 Whole-cell voltage clamp
 P42-p92
Neurotransmitter release: catecholamines1
Decreased
Description: Decreased cerebellar evoked medial prefrontal cortex dopamine release
Exp Paradigm: Males only
 In vivo amperometry
 Unreported
Action potential property: firing rate5
Increased
Description: Mutants show increased evoked spike rate in l2/l3 pyramidal neurons of the s1 somatosensory cortex compared with controls.
Exp Paradigm: NA
 Whole-cell voltage clamp
 P17-p23
Network excitability5
Decreased
Description: Mutants show decrease in whisker evoked population firing rate in l2/3 rs cells compared with controls. mutants show decrease in the fraction of whisker responsive l2/l3 regular spiking units compared with controls. mutants show a decrease in pairwise tuning similarity (signal correlation) between simultaneously recorded l2/3 rs neurons , reduced noise correlation and reduced firing synchrony compared with controls.
Exp Paradigm: Single unit fast and regular spikes were recorded in c1-2 and d1-2 whisker columns in the vrc (ventral retrosplenial cortex) with laminar polytrodes in l4 and l2/3 of s1 in adult urethane-anesthetized mice (p42-92). spiking was measured in response to calibrated whisker deflections.
 Whole-cell voltage clamp
 P17-p23
Synaptic transmission5
Increased
Description: Mutants show increase in e-i conductance ratio compared with controls, indicating a greater decrease in ipsc than epsc.
Exp Paradigm: L4-evoked feedforward excitatory and inhibitory currents converging onto single l2/3 pyramidal cells were measured in the s1 somatosensory cortex in acute slices. epsc amplitudes were compared at the minimum l4 stimulation intensity required to evoke a detectable epsc and at peak current amplitude.
 Whole-cell voltage clamp
 P17-p23
Epsp-spike relationship5
Decreased
Description: Mutants show smaller feedforward epsc amplitudes and decrease in area under mean epsc input-output curves compared with controls.
Exp Paradigm: L4-evoked feedforward excitatory and inhibitory currents converging onto single l2/3 pyramidal cells were measured in the s1 somatosensory cortex in acute slices. epsc amplitudes were compared at the minimum l4 stimulation intensity required to evoke a detectable epsc and at peak current amplitude.
 Whole-cell voltage clamp
 P17-p23
Stimulus-spike relationship: inhibitory5
Decreased
Description: Mutants show decrease in ipscs compared with controls.
Exp Paradigm: L4-evoked feedforward excitatory and inhibitory currents converging onto single l2/3 pyramidal cells were measured in the s1 somatosensory cortex in acute slices. epsc amplitudes were compared at the minimum l4 stimulation intensity required to evoke a detectable epsc and at peak current amplitude.
 Whole-cell voltage clamp
 P17-p23
Repetitive digging3
Increased
Description: Increased burying behavior
Exp Paradigm: Marble burying assay
 Marble-burying test
 4, 8 weeks, 2 months
Circling2
Increased
Description: Increased circling demonstrated by more revelving in counterclockwise direction
Exp Paradigm: Open field test
 Open field test
 10-17 weeks
Stereotypy3
Increased
Description: Increased levels of stereotypy counts
Exp Paradigm: Open field test
 Open field test
 Unreported
Stereotypy2
Increased
Description: Increased levels of stereotypy counts
Exp Paradigm: Open field test
 Open field test
 10-17 weeks
Seizures2
Increased
Description: Increased susceptibility to sound-induced seizures indicated by sequential seizure response of wild running, tonic-clonic seizures, and respiratory arrest, leading to death
Exp Paradigm: Audiogenic seizure assay
 Audiogenic seizure test
 10-17 weeks
Sensory-evoked response: excitation: tactile stimulus5
Decreased
Description: Mutants show reduced firing of l2/3 fast but not regular spiking units in the vrc in response to whisker deflections compared with controls, indicating feedforward inhibition is reduced in vivo. mutants show no change in the fraction of l2/l3 regular spiking units that were responsive to whisker stimulation compared with controls.
Exp Paradigm: Single unit fast and regular spikes were recorded in c1-2 and d1-2 whisker columns in the vrc (ventral retrosplenial cortex) with laminar polytrodes in l4 and l2/3 of s1 in adult urethane-anesthetized mice (p42-92). spiking was measured in response to calibrated whisker deflections.
 Whole-cell voltage clamp
 P42-p92
Sensory-evoked response: excitation: tactile stimulus5
Decreased
Description: Mutants show decrease in firing of l2/l3 regular spiking units in response to whisker deflection in anesthetized juveniles and awake adults engaged in a visual detection task compared with controls. mutants show no change in the fraction of l2/l3 regular spiking units that were responsive to whisker stimulation compared with controls. mutants show no change in spike latency, jitter and tuning sharpness compared with controls. mutants show no change in firing rate of l4 regular spiking units in the vrc in response to whisker deflections compared with controls.
Exp Paradigm: Single unit regular spikes were recorded in c1-2 and d1-2 whisker columns in the vrc (ventral retrosplenial cortex) with laminar polytrodes in l4 and l2/3 of s1 in adult urethane-anesthetized mice. spiking was measured in response to calibrated whisker deflections. jitter is the standard deviation of spike times 4-50 ms post-stimulus, measured across all whiskers within a units whisker receptive field. tuning sharpness is the firing rate evoked by the bw (best whisker) divided by the sum of the bw-evoked firing rate plus mean firing rate to all immediately adjacent whiskers.
 Whole-cell voltage clamp
 2.5 weeks - 3.14 weeks, 2 months
Tissue weight2
Increased
Description: Increased testis weight
Exp Paradigm: General observations
 General observations
 10-17 weeks
Anxiety3
Increased
Description: Increased anxiety indicated by less time in open arm per entry
Exp Paradigm: Elevated plus maze test
 Elevated plus maze test
 4, 8 weeks
Protein phosphorylation3
Decreased
Description: Decreased phosphorylation levels of gsk3alpha in hippocampus
Exp Paradigm: Kinase phosphorylation levels
 Elisa
 Unreported
Protein phosphorylation3
Increased
Description: Increased phosphorylation levels of akt1, akt2 and erk1/2 in hippocampus
Exp Paradigm: Kinase phosphorylation levels
 Elisa
 Unreported
Size/growth2
 No change
 General observations
 10-17 weeks
Adaptive immune response: b cells antibody production: igg3
 No change
 Elisa
 Unreported
Dendritic architecture: spine density2
 No change
 Golgi-cox staining
 11 weeks
Action potential property: amplitude5
 No change
 Whole-cell current clamp
 P17-p23
Action potential property: firing rate5
 No change
 Whole-cell current clamp
 P17-p23
Action potential property: firing rate5
 No change
 Cell-attached patch clamp
 P17-p23
Action potential property: firing rate5
 No change
 Whole-cell voltage clamp
 2.5 weeks - 3.14 weeks, 2 months
Action potential property: rate of depolarization5
 No change
 Whole-cell current clamp
 P17-p23
Decay kinetics of miniature post synaptic currents5
 No change
 Whole-cell current clamp
 P17-p23
Decay kinetics of miniature post synaptic currents5
 No change
 Whole-cell voltage clamp
 P17-p23
Intrinsic membrane properties5
 No change
 Whole-cell voltage clamp
 P17-p23
Membrane potential5
 No change
 Whole-cell voltage clamp
 P17-p23
Network excitability5
 No change
 Whole-cell current clamp
 P17-p23
Neuronal activation4
 No change
 Whole-cell voltage clamp
 P17-p23
Spontaneous post synaptic event amplitude: excitatory currents5
 No change
 Whole-cell voltage clamp
 P17-p23
Spontaneous post synaptic event amplitude: inhibitory currents5
 No change
 Whole-cell voltage clamp
 P17-p23
Spontaneous post synaptic event frequency: excitatory currents5
 No change
 Whole-cell voltage clamp
 P17-p23
Spontaneous post synaptic event frequency: inhibitory currents5
 No change
 Whole-cell voltage clamp
 P17-p23
Synaptic plasticity5
 No change
 Whole-cell current clamp
 P17-p23
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_1_KO_HM_5HT2BAG+D1AG+PI3KINHIBITOR

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Reward reinforced choice behavior1
Decreased
Description: Treatment with a pi3 k inhibitor construct instead of glua1 eliminates the benefits of treatment with the cocktail of 5ht and dopamine agonists and reduces cue conditioned choice learning to the level of fmr1 ko mice
Exp Paradigm: Y maze learning test was carried out using an elevated y maze, one start arma nd two goal arms. the food well located at the end of each goal arm was filled with sucrose sweetened non fat dairy milk as a reward. after 18 h food fasting with no restriction on water access, mice were first habituated to y maze and milk reward. mice were then trained and tested on a conditional learning task using interchangeable floor inserts, either plain or white or black wire mesh, covering the whole of the start arm, this was the conditional cue. the presence of the plain white insert indicated the presence of milk reward in the right goal arm and the black wire mesh indicated the milk reward was present in the left arm. mice received 14 training sessions consisting of 10
 Y-maze test
 P29
Cued or contextual fear conditioning1
Decreased
Description: Treatment with a pi3 k inhibitor eliminates the benefits of treatment with the cocktail of 5ht and dopamine agonists and reduces learning mediated freesing to the level of fmr1 ko mice
Exp Paradigm: Trace fear conditioning traning consisted of a 15-sec white noise conditioned stimulus (cs) and a 0.5 s scrambled foot shock (us). mice were acclimated for 60 sec and then presented with seven cs-trace-us intertrial interval trials ( trace, 30 sex, iti, 210 sec). one day after training, mice were acclimated for 60 sec followed by 7 cs iti trials ( iti, 30 sec) in a novel chamber to test for trace fear memory.
 Fear conditioning test
 P29
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_1_KO_HM_GLUA1CT-5HT2BAG+D1AG

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Reward reinforced choice behavior1
Decreased
Description: Infecting with the dominant negative glua1 ct construct instead of glua1 eliminates the benefits of treatment with the cocktail of 5ht and dopamine agonists and reduces cue conditioned choice learning to the level of fmr1 ko mice
Exp Paradigm: Y maze learning test was carried out using an elevated y maze, one start arma nd two goal arms. the food well located at the end of each goal arm was filled with sucrose sweetened non fat dairy milk as a reward. after 18 h food fasting with no restriction on water access, mice were first habituated to y maze and milk reward. mice were then trained and tested on a conditional learning task using interchangeable floor inserts, either plain or white or black wire mesh, covering the whole of the start arm, this was the conditional cue. the presence of the plain white insert indicated the presence of milk reward in the right goal arm and the black wire mesh indicated the milk reward was present in the left arm. mice received 14 training sessions consisting of 10
 Y-maze test
 P29
Cued or contextual fear conditioning1
Decreased
Description: Infecting with the dominant negative glua1 ct construct instead of glua1 eliminates the benefits of treatment with the cocktail of 5ht and dopamine agonists and reduces learning mediated freezing to the level of fmr1 ko mice
Exp Paradigm: Trace fear conditioning traning consisted of a 15-sec white noise conditioned stimulus (cs) and a 0.5 s scrambled foot shock (us). mice were acclimated for 60 sec and then presented with seven cs-trace-us intertrial interval trials ( trace, 30 sex, iti, 210 sec). one day after training, mice were acclimated for 60 sec followed by 7 cs iti trials ( iti, 30 sec) in a novel chamber to test for trace fear memory.
 Fear conditioning test
 P29
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_SYNGAP1_9_KO_FMR1_DM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Synaptic plasticity: hippocampal ltd1
Increased
Description: Syngap1 het: fmr1 null male double ko mice have a significant increase in the magnitidue of mglur dependent ltd in the hippocampus compared to wild type littermate controls and authors note the increase in magnitude is more than what is seen in the individual mutations (syngap1 het or fmr1-/y)
Exp Paradigm: NA
 Field potential recordings
 3-4.5 weeks
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_12_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Cytokine levels: pro-inflammatory1
Decreased
Description: Mutants show decreased proinflammatory cytokine transcript expression of il6 and tnfalpha compared to controls.
Exp Paradigm: NA
 Quantitative pcr (qrt-pcr)
 Adult
Cytokine levels: anti-inflammatory1
 No change
 Quantitative pcr (qrt-pcr)
 Adult
Cytokine levels: chemokine1
 No change
 Quantitative pcr (qrt-pcr)
 Adult
Cytokine levels: pro-inflammatory1
 No change
 Quantitative pcr (qrt-pcr)
 Adult
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Sensory, Social behavior

M_FMR1_13_KD

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Social memory1
Decreased
Description: Fmr1-sirna injected mice show decrease in preference for an unfamiliar over a familiar mouse compared with controls.
Exp Paradigm: NA
 U-field assay
 Adult
Object recognition memory1
Decreased
Description: Fmr1-sirna injected mice show decrease in time spent with an unfamiliar object over a familiar object compared with controls.
Exp Paradigm: NA
 Object preference test
 Adult
Targeted expression1
Decreased
Description: Fmr1-sirna injected mice show decrease in fmr1 transcript in the dorsal striatum, 2 days after injection.
Exp Paradigm: Striatal tissue was used for qrt pcr.
 Quantitative pcr (qrt-pcr)
 Adult
Repetitive digging1
 No change
 Home cage behavior
 Adult
Self grooming: perseveration1
 No change
 Grooming behavior assessments
 Adult
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Maternal behavior, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Seizure, Sensory

M_FMR1_14_KO_HE

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Sensorimotor gating: tactile cue1
Increased
Description: Mutants show increased responsivity to an air puff stimulus delivered to back hairy skin.
Exp Paradigm: NA
 Response to air puff
 6-8 weeks
Sensorimotor gating: tactile cue1
Increased
Description: Mutants exhibited hairy skin hypersensitivity, measured by an increase of tactile prepulse inhibition of an acoustic startle response assay.
Exp Paradigm: NA
 Prepulse inhibition
 6-8 weeks
Startle response: acoustic stimulus1
 No change
 Acoustic startle reflex test
 6-8 weeks
 Not Reported:

M_FMR1_15_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Hyperactivity1
Increased
Description: Increase in the nunber of squares covered
 Open field test
 2 months
Repetitive digging1
Decreased
Description: Decrease in the number of marbles buried
 Marble-burying test
 2 months
Nest building behavior1
Increased
Description: Decreased nest construction quality
 Nest building assay
 2 months
Exploratory activity: Habituation1
Decreased
Description: Persistent increase in the nunber of squares covered 10min and 24hr after the first trial indicating a decreased in habituation
 Open field test
 2 months
Cued or contextual fear conditioning: Memory of context1
Decreased
Description: Decrease in the freezing response
 Fear conditioning test
 2 months
 Not Reported:


Interactor Symbol Interactor Name Interactor Organism Entrez ID Uniprot ID Interaction Type Evidence Reference
11-Sep septin 11 55752 Q9NVA2 PAR-CLIP
Ascano M Jr , et al. 2012
2-Sep septin 2 4735 Q15019 PAR-CLIP
Ascano M Jr , et al. 2012
5-Mar membrane-associated ring finger (C3HC4) 5 54708 Q9NX47 PAR-CLIP
Ascano M Jr , et al. 2012
6-Mar membrane-associated ring finger (C3HC4) 6, E3 ubiquitin protein ligase 10299 B4DT33 PAR-CLIP
Ascano M Jr , et al. 2012
6-Sep septin 6 23157 Q14141 PAR-CLIP
Ascano M Jr , et al. 2012
7-Mar membrane-associated ring finger (C3HC4) 7, E3 ubiquitin protein ligase 64844 Q9H992 PAR-CLIP
Ascano M Jr , et al. 2012
8-Mar membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase 220972 Q5T0T0 PAR-CLIP
Ascano M Jr , et al. 2012
8-Sep septin 8 23176 Q92599 PAR-CLIP
Ascano M Jr , et al. 2012
9-Mar membrane-associated ring finger (C3HC4) 9 92979 Q86YJ5 PAR-CLIP
Ascano M Jr , et al. 2012
9-Sep septin 9 10801 Q9UHD8 PAR-CLIP
Ascano M Jr , et al. 2012
AAAS achalasia, adrenocortical insufficiency, alacrimia 8086 Q9NRG9 PAR-CLIP
Ascano M Jr , et al. 2012
AAGAB alpha- and gamma-adaptin binding protein 79719 Q6PD74 PAR-CLIP
Ascano M Jr , et al. 2012
AAMP angio-associated, migratory cell protein 14 Q13685 PAR-CLIP
Ascano M Jr , et al. 2012
AARS alanyl-tRNA synthetase 16 P49588 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AARS2 alanyl-tRNA synthetase 2, mitochondrial 57505 Q5JTZ9 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AARSD1 alanyl-tRNA synthetase domain containing 1 80755 Q9BTE6 PAR-CLIP
Ascano M Jr , et al. 2012
AASDH aminoadipate-semialdehyde dehydrogenase 132949 Q4L235 PAR-CLIP
Ascano M Jr , et al. 2012
AASDHPPT aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 60496 Q9NRN7 PAR-CLIP
Ascano M Jr , et al. 2012
AASS aminoadipate-semialdehyde synthase 10157 A4D0W4 PAR-CLIP
Ascano M Jr , et al. 2012
AATF apoptosis antagonizing transcription factor 26574 Q9NY61 PAR-CLIP
Ascano M Jr , et al. 2012
ABAT 4-aminobutyrate aminotransferase 18 P80404 PAR-CLIP
Ascano M Jr , et al. 2012
ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 154664 Q86UQ4 PAR-CLIP
Ascano M Jr , et al. 2012
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 24 P78363 PAR-CLIP
Ascano M Jr , et al. 2012
ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 23461 Q8WWZ7 PAR-CLIP
Ascano M Jr , et al. 2012
ABCB10 ATP-binding cassette, sub-family B (MDR/TAP), member 10 23456 Q9NRK6 PAR-CLIP
Ascano M Jr , et al. 2012
ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 22 O75027 PAR-CLIP
Ascano M Jr , et al. 2012
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 4363 P33527 PAR-CLIP
Ascano M Jr , et al. 2012
ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 89845 Q5T3U5 PAR-CLIP
Ascano M Jr , et al. 2012
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 8714 O15438 PAR-CLIP
Ascano M Jr , et al. 2012
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 10257 O15439 PAR-CLIP
Ascano M Jr , et al. 2012
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 10057 O15440 PAR-CLIP
Ascano M Jr , et al. 2012
ABCD3 ATP-binding cassette, sub-family D (ALD), member 3 5825 P28288 PAR-CLIP
Ascano M Jr , et al. 2012
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 6059 P61221 PAR-CLIP
Ascano M Jr , et al. 2012
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 23 Q8NE71 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 10061 Q75MJ1 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ABHD10 abhydrolase domain containing 10 55347 Q9NUJ1 PAR-CLIP
Ascano M Jr , et al. 2012
ABHD12 abhydrolase domain containing 12 26090 Q8N2K0 PAR-CLIP
Ascano M Jr , et al. 2012
ABHD13 abhydrolase domain containing 13 84945 Q7L211 PAR-CLIP
Ascano M Jr , et al. 2012
ABHD15 abhydrolase domain containing 15 116236 Q6UXT9 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ABHD16A abhydrolase domain containing 16A 7920 B3KNX9 PAR-CLIP
Ascano M Jr , et al. 2012
ABHD2 abhydrolase domain containing 2 11057 P08910 PAR-CLIP
Ascano M Jr , et al. 2012
ABHD5 abhydrolase domain containing 5 51099 Q8WTS1 PAR-CLIP
Ascano M Jr , et al. 2012
ABHD8 abhydrolase domain containing 8 79575 B2C6G3 PAR-CLIP
Ascano M Jr , et al. 2012
ABI1 abl-interactor 1 10006 Q8IZP0 PAR-CLIP
Ascano M Jr , et al. 2012
ABI2 abl-interactor 2 10152 Q9NYB9 PAR-CLIP
Ascano M Jr , et al. 2012
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 25 P00519 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 27 P42684 PAR-CLIP
Ascano M Jr , et al. 2012
ABLIM1 actin binding LIM protein 1 3983 O14639 PAR-CLIP
Ascano M Jr , et al. 2012
ABT1 activator of basal transcription 1 29777 Q9ULW3 PAR-CLIP
Ascano M Jr , et al. 2012
ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 25841 Q8N961 PAR-CLIP
Ascano M Jr , et al. 2012
ACAA2 acetyl-CoA acyltransferase 2 10449 B3KNP8 PAR-CLIP
Ascano M Jr , et al. 2012
ACACA acetyl-CoA carboxylase alpha 31 Q13085 PAR-CLIP
Ascano M Jr , et al. 2012
ACACB acetyl-CoA carboxylase beta 32 O00763 PAR-CLIP
Ascano M Jr , et al. 2012
ACAD10 acyl-CoA dehydrogenase family, member 10 80724 Q6JQN1 PAR-CLIP
Ascano M Jr , et al. 2012
ACAD9 acyl-CoA dehydrogenase family, member 9 28976 Q9H845 PAR-CLIP
Ascano M Jr , et al. 2012
ACADL acyl-CoA dehydrogenase, long chain 33 P28330 PAR-CLIP
Ascano M Jr , et al. 2012
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain 34 P11310 PAR-CLIP
Ascano M Jr , et al. 2012
ACAP2 ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 23527 Q15057 PAR-CLIP
Ascano M Jr , et al. 2012
ACAP3 ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 116983 Q8WTZ1 PAR-CLIP
Ascano M Jr , et al. 2012
ACAT1 acetyl-CoA acetyltransferase 1 38 P24752 PAR-CLIP
Ascano M Jr , et al. 2012
ACAT2 acetyl-CoA acetyltransferase 2 39 Q9BWD1 PAR-CLIP
Ascano M Jr , et al. 2012
ACBD5 acyl-CoA binding domain containing 5 91452 Q5T8D3 PAR-CLIP
Ascano M Jr , et al. 2012
ACBD6 acyl-CoA binding domain containing 6 84320 B2RAA8 PAR-CLIP
Ascano M Jr , et al. 2012
ACER3 alkaline ceramidase 3 55331 Q9NUN7 PAR-CLIP
Ascano M Jr , et al. 2012
ACIN1 apoptotic chromatin condensation inducer 1 22985 Q9UKV3 PAR-CLIP
Ascano M Jr , et al. 2012
ACN9 ACN9 homolog (S. cerevisiae) 57001 Q9NRP4 PAR-CLIP
Ascano M Jr , et al. 2012
ACO1 aconitase 1, soluble 48 P21399 PAR-CLIP
Ascano M Jr , et al. 2012
ACOT7 acyl-CoA thioesterase 7 11332 O00154 IP; LC-MS/MS; IP/WB
Li J , et al. 2016
ACOT9 acyl-CoA thioesterase 9 23597 Q9Y305 PAR-CLIP
Ascano M Jr , et al. 2012
ACOX1 acyl-CoA oxidase 1, palmitoyl 51 B4DK61 PAR-CLIP
Ascano M Jr , et al. 2012
ACP1 acid phosphatase 1, soluble 52 B5MCC7 PAR-CLIP
Ascano M Jr , et al. 2012
ACP2 acid phosphatase 2, lysosomal 53 P11117 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ACP6 acid phosphatase 6, lysophosphatidic 51205 Q9NPH0 PAR-CLIP
Ascano M Jr , et al. 2012
ACSF3 acyl-CoA synthetase family member 3 197322 Q4G176 PAR-CLIP
Ascano M Jr , et al. 2012
ACSL1 acyl-CoA synthetase long-chain family member 1 2180 P33121 PAR-CLIP
Ascano M Jr , et al. 2012
ACSL3 acyl-CoA synthetase long-chain family member 3 2181 B3KMA6 PAR-CLIP
Ascano M Jr , et al. 2012
ACSL4 acyl-CoA synthetase long-chain family member 4 2182 O60488 PAR-CLIP
Ascano M Jr , et al. 2012
ACSS1 acyl-CoA synthetase short-chain family member 1 84532 Q9NUB1 PAR-CLIP
Ascano M Jr , et al. 2012
ACTA1 actin, alpha 1, skeletal muscle 58 P68133 PAR-CLIP
Ascano M Jr , et al. 2012
ACTG1 actin, gamma 1 71 P63261 PAR-CLIP
Ascano M Jr , et al. 2012
ACTL6A actin-like 6A 86 O96019 PAR-CLIP
Ascano M Jr , et al. 2012
ACTN1 actinin, alpha 1 87 P12814 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ACTN4 actinin, alpha 4 81 O43707 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ACTR1A ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) 10121 P61163 PAR-CLIP
Ascano M Jr , et al. 2012
ACTR1B ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 10120 P42025 PAR-CLIP
Ascano M Jr , et al. 2012
ACTR2 ARP2 actin-related protein 2 homolog (yeast) 10097 E9PF41 PAR-CLIP
Ascano M Jr , et al. 2012
ACTR3 ARP3 actin-related protein 3 homolog (yeast) 10096 P61158 PAR-CLIP
Ascano M Jr , et al. 2012
ACTR3B ARP3 actin-related protein 3 homolog B (yeast) 57180 Q59GD5 PAR-CLIP
Ascano M Jr , et al. 2012
ACTR8 ARP8 actin-related protein 8 homolog (yeast) 93973 Q9H981 PAR-CLIP
Ascano M Jr , et al. 2012
ACVR1 activin A receptor, type I 90 D3DPA4 PAR-CLIP
Ascano M Jr , et al. 2012
ACVR1B activin A receptor, type IB 91 P36896 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ACVR2A activin A receptor, type IIA 92 P27037 PAR-CLIP
Ascano M Jr , et al. 2012
ACVR2B activin A receptor, type IIB 93 Q13705 PAR-CLIP
Ascano M Jr , et al. 2012
ADAL adenosine deaminase-like 161823 Q6DHV7 PAR-CLIP
Ascano M Jr , et al. 2012
ADAM10 ADAM metallopeptidase domain 10 102 O14672 PAR-CLIP
Ascano M Jr , et al. 2012
ADAM15 ADAM metallopeptidase domain 15 8751 Q13444 PAR-CLIP
Ascano M Jr , et al. 2012
ADAM17 ADAM metallopeptidase domain 17 6868 B2RNB2 PAR-CLIP
Ascano M Jr , et al. 2012
ADAM22 ADAM metallopeptidase domain 22 53616 Q9P0K1 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ADAM23 ADAM metallopeptidase domain 23 8745 O75077 PAR-CLIP
Ascano M Jr , et al. 2012
ADAM28 ADAM metallopeptidase domain 28 10863 Q9UKQ2 PAR-CLIP
Ascano M Jr , et al. 2012
ADAM9 ADAM metallopeptidase domain 9 8754 Q13443 PAR-CLIP
Ascano M Jr , et al. 2012
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 9510 Q9UHI8 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 81792 P58397 PAR-CLIP
Ascano M Jr , et al. 2012
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 9508 B7Z2U9 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 11095 Q5FWF1 PAR-CLIP
Ascano M Jr , et al. 2012
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 56999 Q9P2N4 PAR-CLIP
Ascano M Jr , et al. 2012
ADAMTSL2 ADAMTS-like 2 9719 Q86TH1 PAR-CLIP
Ascano M Jr , et al. 2012
ADAP2 ArfGAP with dual PH domains 2 55803 Q9NPF8 PAR-CLIP
Ascano M Jr , et al. 2012
ADAR adenosine deaminase, RNA-specific 103 P55265 IP; LC-MS/MS
Li J , et al. 2016
ADARB2 adenosine deaminase, RNA-specific, B2 105 Q9NS39 PAR-CLIP
Ascano M Jr , et al. 2012
ADAT1 adenosine deaminase, tRNA-specific 1 23536 Q9BUB4 PAR-CLIP
Ascano M Jr , et al. 2012
ADAT2 adenosine deaminase, tRNA-specific 2 134637 Q7Z6V5 PAR-CLIP
Ascano M Jr , et al. 2012
ADCK2 aarF domain containing kinase 2 90956 A4D1T6 PAR-CLIP
Ascano M Jr , et al. 2012
ADCK3 aarF domain containing kinase 3 56997 Q8NI60 PAR-CLIP
Ascano M Jr , et al. 2012
ADCK4 aarF domain containing kinase 4 79934 Q96D53 PAR-CLIP
Ascano M Jr , et al. 2012
ADCY3 adenylate cyclase 3 109 B3KT86 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ADCY6 adenylate cyclase 6 112 O43306 PAR-CLIP
Ascano M Jr , et al. 2012
ADCY7 adenylate cyclase 7 113 P51828 PAR-CLIP
Ascano M Jr , et al. 2012
ADCY9 adenylate cyclase 9 115 O60503 PAR-CLIP
Ascano M Jr , et al. 2012
ADD2 adducin 2 (beta) 119 P35612 PAR-CLIP
Ascano M Jr , et al. 2012
ADD3 adducin 3 (gamma) 120 Q9UEY8 PAR-CLIP
Ascano M Jr , et al. 2012
ADH5 alcohol dehydrogenase 5 (class III), chi polypeptide 128 P11766 PAR-CLIP
Ascano M Jr , et al. 2012
ADIPOR1 adiponectin receptor 1 51094 Q96A54 PAR-CLIP
Ascano M Jr , et al. 2012
ADIPOR2 adiponectin receptor 2 79602 Q86V24 PAR-CLIP
Ascano M Jr , et al. 2012
ADK adenosine kinase 132 P55263 PAR-CLIP
Ascano M Jr , et al. 2012
ADNP2 ADNP homeobox 2 22850 Q6IQ32 PAR-CLIP
Ascano M Jr , et al. 2012
ADO 2-aminoethanethiol (cysteamine) dioxygenase 84890 B3KXN9 PAR-CLIP
Ascano M Jr , et al. 2012
ADORA2B adenosine A2b receptor 136 P29275 PAR-CLIP
Ascano M Jr , et al. 2012
ADPGK ADP-dependent glucokinase 83440 Q9BRR6 PAR-CLIP
Ascano M Jr , et al. 2012
ADPRHL2 ADP-ribosylhydrolase like 2 54936 Q9NX46 PAR-CLIP
Ascano M Jr , et al. 2012
ADRB1 adrenoceptor beta 1 153 P08588 PAR-CLIP
Ascano M Jr , et al. 2012
ADRBK2 adrenergic, beta, receptor kinase 2 157 P35626 PAR-CLIP
Ascano M Jr , et al. 2012
ADRM1 adhesion regulating molecule 1 11047 Q16186 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ADSL adenylosuccinate lyase 158 P30566 PAR-CLIP
Ascano M Jr , et al. 2012
ADSS adenylosuccinate synthase 159 P30520 PAR-CLIP
Ascano M Jr , et al. 2012
AEBP2 AE binding protein 2 121536 Q6ZN18 PAR-CLIP
Ascano M Jr , et al. 2012
AEN apoptosis enhancing nuclease 64782 Q8WTP8 PAR-CLIP
Ascano M Jr , et al. 2012
AES amino-terminal enhancer of split 166 Q08117 PAR-CLIP
Ascano M Jr , et al. 2012
AFF1 AF4/FMR2 family member 1 4299 P51825 PAR-CLIP
Ascano M Jr , et al. 2012
AFF2 AF4/FMR2 family, member 2 2334 P51816 PAR-CLIP
Ascano M Jr , et al. 2012
AFG3L2 AFG3 ATPase family member 3-like 2 (S. cerevisiae) 10939 Q8TA92 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AFTPH aftiphilin 54812 Q6ULP2 PAR-CLIP
Ascano M Jr , et al. 2012
AGAP6 ArfGAP with GTPase domain, ankyrin repeat and PH domain 6 414189 Q5VW22 PAR-CLIP
Ascano M Jr , et al. 2012
AGBL3 ATP/GTP binding protein-like 3 340351 Q8NEM8 PAR-CLIP
Ascano M Jr , et al. 2012
AGBL4 ATP/GTP binding protein-like 4 84871 Q5VU57 PAR-CLIP
Ascano M Jr , et al. 2012
AGBL5 ATP/GTP binding protein-like 5 60509 Q8NDL9 PAR-CLIP
Ascano M Jr , et al. 2012
AGFG1 ArfGAP with FG repeats 1 3267 P52594 PAR-CLIP
Ascano M Jr , et al. 2012
AGGF1 angiogenic factor with G patch and FHA domains 1 55109 Q8N302 PAR-CLIP
Ascano M Jr , et al. 2012
AGK acylglycerol kinase 55750 A4D1U5 PAR-CLIP
Ascano M Jr , et al. 2012
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase 178 P35573 PAR-CLIP
Ascano M Jr , et al. 2012
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 10554 Q99943 PAR-CLIP
Ascano M Jr , et al. 2012
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 10555 O15120 PAR-CLIP
Ascano M Jr , et al. 2012
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 55326 Q9NUQ2 PAR-CLIP
Ascano M Jr , et al. 2012
AGPAT6 1-acylglycerol-3-phosphate O-acyltransferase 6 137964 Q2TU73 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 84803 Q53EU6 PAR-CLIP
Ascano M Jr , et al. 2012
AGPS alkylglycerone phosphate synthase 8540 O00116 PAR-CLIP
Ascano M Jr , et al. 2012
AGTR1 angiotensin II receptor, type 1 185 P30556 PAR-CLIP
Ascano M Jr , et al. 2012
AGTRAP angiotensin II receptor-associated protein 57085 Q6RW13 PAR-CLIP
Ascano M Jr , et al. 2012
AHCTF1 AT hook containing transcription factor 1 25909 Q8WYP5 PAR-CLIP
Ascano M Jr , et al. 2012
AHCY adenosylhomocysteinase 191 P23526 PAR-CLIP
Ascano M Jr , et al. 2012
AHCYL1 adenosylhomocysteinase-like 1 10768 O43865 PAR-CLIP
Ascano M Jr , et al. 2012
AHCYL2 adenosylhomocysteinase-like 2 23382 Q96HN2 PAR-CLIP
Ascano M Jr , et al. 2012
AHI1 Abelson helper integration site 1 54806 Q4FD35 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AHNAK AHNAK nucleoprotein 79026 Q09666 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AHNAK2 AHNAK nucleoprotein 2 113146 Q8IVF2 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AHR aryl hydrocarbon receptor 196 P35869 PAR-CLIP
Ascano M Jr , et al. 2012
AHRR aryl-hydrocarbon receptor repressor 57491 A9YTQ3 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AHSA1 AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) 10598 O95433 PAR-CLIP
Ascano M Jr , et al. 2012
AHSA2 AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) 130872 Q719I0 PAR-CLIP
Ascano M Jr , et al. 2012
AIDA axin interactor, dorsalization associated 64853 Q96BJ3 PAR-CLIP
Ascano M Jr , et al. 2012
AIF1L allograft inflammatory factor 1-like 83543 Q9BQI0 PAR-CLIP
Ascano M Jr , et al. 2012
AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 9131 O95831 PAR-CLIP
Ascano M Jr , et al. 2012
AIFM2 apoptosis-inducing factor, mitochondrion-associated, 2 84883 Q9BRQ8 PAR-CLIP
Ascano M Jr , et al. 2012
AIG1 androgen-induced 1 51390 Q9NVV5 PAR-CLIP
Ascano M Jr , et al. 2012
AIM1 absent in melanoma 1 202 B3KPT0 PAR-CLIP
Ascano M Jr , et al. 2012
AIM2 absent in melanoma 2 9447 O14862 PAR-CLIP
Ascano M Jr , et al. 2012
AIMP1 aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 9255 B4DNK3 PAR-CLIP
Ascano M Jr , et al. 2012
AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 7965 Q13155 PAR-CLIP
Ascano M Jr , et al. 2012
AIP aryl hydrocarbon receptor interacting protein 9049 O00170 PAR-CLIP
Ascano M Jr , et al. 2012
AK2 adenylate kinase 2 204 P54819 PAR-CLIP
Ascano M Jr , et al. 2012
AK3 adenylate kinase 3 50808 Q7Z4Y4 PAR-CLIP
Ascano M Jr , et al. 2012
AK4 adenylate kinase 4 205 P27144 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP1 A kinase (PRKA) anchor protein 1 8165 B4DN86 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP10 A kinase (PRKA) anchor protein 10 11216 O43572 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP11 A kinase (PRKA) anchor protein 11 11215 Q9UKA4 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP12 A kinase (PRKA) anchor protein 12 9590 Q02952 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP13 A kinase (PRKA) anchor protein 13 11214 B0AZU4 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP2 A kinase (PRKA) anchor protein 2 11217 Q9Y2D5 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP7 A kinase (PRKA) anchor protein 7 9465 O43687 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP8 A kinase (PRKA) anchor protein 8 10270 O43823 PAR-CLIP
Ascano M Jr , et al. 2012
AKAP8L A kinase (PRKA) anchor protein 8-like 26993 Q9ULX6 PAR-CLIP
Ascano M Jr , et al. 2012
AKD1 adenylate kinase domain containing 1 221264 Q5TCS8 PAR-CLIP
Ascano M Jr , et al. 2012
AKIP1 A kinase (PRKA) interacting protein 1 56672 Q9NQ31 PAR-CLIP
Ascano M Jr , et al. 2012
AKIRIN1 akirin 1 79647 Q9H9L7 PAR-CLIP
Ascano M Jr , et al. 2012
AKIRIN2 akirin 2 55122 Q53H80 PAR-CLIP
Ascano M Jr , et al. 2012
AKNAD1 AKNA domain containing 1 254268 Q5T1N1 PAR-CLIP
Ascano M Jr , et al. 2012
AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde reductase) 10327 P14550 PAR-CLIP
Ascano M Jr , et al. 2012
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) 231 P15121 PAR-CLIP
Ascano M Jr , et al. 2012
AKR1D1 aldo-keto reductase family 1, member D1 6718 P51857 PAR-CLIP
Ascano M Jr , et al. 2012
AKR7A3 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 22977 O95154 PAR-CLIP
Ascano M Jr , et al. 2012
AKT1 v-akt murine thymoma viral oncogene homolog 1 207 P31749 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AKT1S1 AKT1 substrate 1 (proline-rich) 84335 Q96B36 PAR-CLIP
Ascano M Jr , et al. 2012
AKT2 v-akt murine thymoma viral oncogene homolog 2 208 B4DG79 PAR-CLIP
Ascano M Jr , et al. 2012
ALAD aminolevulinate dehydratase 210 P13716 PAR-CLIP
Ascano M Jr , et al. 2012
ALAS1 aminolevulinate, delta-, synthase 1 211 P13196 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ALAS2 aminolevulinate, delta-, synthase 2 212 P22557 PAR-CLIP
Ascano M Jr , et al. 2012
ALCAM activated leukocyte cell adhesion molecule 214 Q13740 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH18A1 aldehyde dehydrogenase 18 family, member A1 5832 P54886 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH1A2 aldehyde dehydrogenase 1 family, member A2 8854 O94788 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 219 P30837 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 224 P51648 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 8659 P30038 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH5A1 aldehyde dehydrogenase 5 family, member A1 7915 P51649 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 501 P49419 PAR-CLIP
Ascano M Jr , et al. 2012
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 223 B9EKV4 PAR-CLIP
Ascano M Jr , et al. 2012
ALDOC aldolase C, fructose-bisphosphate 230 P09972 Y2H
Sakai Y , et al. 2011
ALG10 ALG10, alpha-1,2-glucosyltransferase 84920 Q5BKT4 PAR-CLIP
Ascano M Jr , et al. 2012
ALG10B ALG10B, alpha-1,2-glucosyltransferase 144245 Q5I7T1 PAR-CLIP
Ascano M Jr , et al. 2012
ALG11 ALG11, alpha-1,2-mannosyltransferase 440138 Q2TAA5 PAR-CLIP
Ascano M Jr , et al. 2012
ALG12 ALG12, alpha-1,6-mannosyltransferase 79087 Q9BV10 PAR-CLIP
Ascano M Jr , et al. 2012
ALG13 ALG13, UDP-N-acetylglucosaminyltransferase subunit 79868 Q9NP73 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ALG2 ALG2, alpha-1,3/1,6-mannosyltransferase 85365 Q9H553 PAR-CLIP
Ascano M Jr , et al. 2012
ALG3 ALG3, alpha-1,3- mannosyltransferase 10195 Q92685 PAR-CLIP
Ascano M Jr , et al. 2012
ALG5 ALG5, dolichyl-phosphate beta-glucosyltransferase 29880 Q9Y673 PAR-CLIP
Ascano M Jr , et al. 2012
ALG6 ALG6, alpha-1,3-glucosyltransferase 29929 Q9Y672 PAR-CLIP
Ascano M Jr , et al. 2012
ALG8 ALG8, alpha-1,3-glucosyltransferase 79053 A6NDW6 PAR-CLIP
Ascano M Jr , et al. 2012
ALG9 ALG9, alpha-1,2-mannosyltransferase 79796 Q9H6U8 PAR-CLIP
Ascano M Jr , et al. 2012
ALKBH1 alkB, alkylation repair homolog 1 (E. coli) 8846 Q13686 PAR-CLIP
Ascano M Jr , et al. 2012
ALKBH2 alkB, alkylation repair homolog 2 (E. coli) 121642 Q6NS38 PAR-CLIP
Ascano M Jr , et al. 2012
ALKBH4 alkB, alkylation repair homolog 4 (E. coli) 54784 Q9NXW9 PAR-CLIP
Ascano M Jr , et al. 2012
ALKBH5 alkB, alkylation repair homolog 5 (E. coli) 54890 Q6P6C2 PAR-CLIP
Ascano M Jr , et al. 2012
ALKBH7 alkB, alkylation repair homolog 7 (E. coli) 84266 Q9BT30 PAR-CLIP
Ascano M Jr , et al. 2012
ALKBH8 alkB, alkylation repair homolog 8 (E. coli) 91801 Q96BT7 PAR-CLIP
Ascano M Jr , et al. 2012
ALMS1 Alstrom syndrome 1 7840 Q8TCU4 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ALOX5 arachidonate 5-lipoxygenase 240 P09917 PAR-CLIP
Ascano M Jr , et al. 2012
ALPK1 alpha-kinase 1 80216 Q96QP1 PAR-CLIP
Ascano M Jr , et al. 2012
ALPK2 alpha-kinase 2 115701 Q86TB3 PAR-CLIP
Ascano M Jr , et al. 2012
ALPL alkaline phosphatase, liver/bone/kidney 249 P05186 PAR-CLIP
Ascano M Jr , et al. 2012
ALS2CR11 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 11 151254 Q53TS8 PAR-CLIP
Ascano M Jr , et al. 2012
ALX1 ALX homeobox 1 8092 Q15699 PAR-CLIP
Ascano M Jr , et al. 2012
ALX4 ALX homeobox 4 60529 Q9H161 PAR-CLIP
Ascano M Jr , et al. 2012
AMACR alpha-methylacyl-CoA racemase 23600 Q9UHK6 PAR-CLIP
Ascano M Jr , et al. 2012
AMBRA1 autophagy/beclin-1 regulator 1 55626 Q9C0C7 PAR-CLIP
Ascano M Jr , et al. 2012
AMD1 adenosylmethionine decarboxylase 1 262 P17707 PAR-CLIP
Ascano M Jr , et al. 2012
AMFR autocrine motility factor receptor, E3 ubiquitin protein ligase 267 Q9UKV5 PAR-CLIP
Ascano M Jr , et al. 2012
AMH anti-Mullerian hormone 268 P03971 PAR-CLIP
Ascano M Jr , et al. 2012
AMIGO2 adhesion molecule with Ig-like domain 2 347902 Q86SJ2 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AMIGO3 adhesion molecule with Ig-like domain 3 386724 Q86WK7 PAR-CLIP
Ascano M Jr , et al. 2012
AMMECR1 Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 9949 Q9Y4X0 PAR-CLIP
Ascano M Jr , et al. 2012
AMMECR1L AMMECR1-like 83607 Q6DCA0 PAR-CLIP
Ascano M Jr , et al. 2012
AMOT angiomotin 154796 Q4VCS5 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AMOTL1 angiomotin like 1 154810 Q8IY63 PAR-CLIP
Ascano M Jr , et al. 2012
AMPD2 adenosine monophosphate deaminase 2 271 B2RB47 PAR-CLIP
Ascano M Jr , et al. 2012
AMZ2 archaelysin family metallopeptidase 2 51321 Q86W34 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC10 anaphase promoting complex subunit 10 10393 Q9UM13 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC11 anaphase promoting complex subunit 11 51529 Q9NYG5 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC13 anaphase promoting complex subunit 13 25847 A8K3Z6 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC16 anaphase promoting complex subunit 16 119504 C5H3H2 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC2 anaphase promoting complex subunit 2 29882 Q9UJX6 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC4 anaphase promoting complex subunit 4 29945 Q9UJX5 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC5 anaphase promoting complex subunit 5 51433 Q9UJX4 PAR-CLIP
Ascano M Jr , et al. 2012
ANAPC7 anaphase promoting complex subunit 7 51434 Q9UJX3 PAR-CLIP
Ascano M Jr , et al. 2012
ANGEL1 angel homolog 1 (Drosophila) 23357 Q9UNK9 PAR-CLIP
Ascano M Jr , et al. 2012
ANGEL2 angel homolog 2 (Drosophila) 90806 Q5VTE6 PAR-CLIP
Ascano M Jr , et al. 2012
ANGPT1 angiopoietin 1 284 Q15389 PAR-CLIP
Ascano M Jr , et al. 2012
ANGPT2 angiopoietin 2 285 O15123 PAR-CLIP
Ascano M Jr , et al. 2012
ANKAR ankyrin and armadillo repeat containing 150709 Q70AK8 PAR-CLIP
Ascano M Jr , et al. 2012
ANKFN1 ankyrin-repeat and fibronectin type III domain containing 1 162282 Q8N957 PAR-CLIP
Ascano M Jr , et al. 2012
ANKFY1 ankyrin repeat and FYVE domain containing 1 51479 Q9P2R3 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANKH ankylosis, progressive homolog (mouse) 56172 Q9HCJ1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKHD1 ankyrin repeat and KH domain containing 1 54882 Q8IWZ3 PAR-CLIP
Ascano M Jr , et al. 2012
ANKHD1-EIF4EBP3 ANKHD1-EIF4EBP3 readthrough 404734 Q8IWZ3 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANKIB1 ankyrin repeat and IBR domain containing 1 54467 Q9P2G1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKMY1 ankyrin repeat and MYND domain containing 1 51281 Q9P2S6 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 57763 Q9H9E1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD10 ankyrin repeat domain 10 55608 Q9NXR5 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD12 ankyrin repeat domain 12 23253 Q6UB98 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD13A ankyrin repeat domain 13A 88455 Q3ZTS7 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD13B ankyrin repeat domain 13B 124930 B3KS27 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD13C ankyrin repeat domain 13C 81573 Q8N6S4 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD16 ankyrin repeat domain 16 54522 Q6P6B7 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD18A ankyrin repeat domain 18A 253650 Q8IVF6 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANKRD18B ankyrin repeat domain 18B 441459 A2A2Z9 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD26 ankyrin repeat domain 26 22852 Q9UPS8 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD26P1 ankyrin repeat domain 26 pseudogene 1 124149 Q6NSI1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 84079 Q96NW4 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANKRD28 ankyrin repeat domain 28 23243 O15084 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD32 ankyrin repeat domain 32 84250 I6L9F1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD33B ankyrin repeat domain 33B 651746 A6NCL7 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD40 ankyrin repeat domain 40 91369 A8IK34 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD43 sosondowah ankyrin repeat domain family member A 134548 Q2M3V2 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD44 ankyrin repeat domain 44 91526 Q8N8A2 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD49 ankyrin repeat domain 49 54851 Q8WVL7 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD50 ankyrin repeat domain 50 57182 Q8TB46 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD54 ankyrin repeat domain 54 129138 Q6NXT1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD57 sosondowah ankyrin repeat domain family member C 65124 Q53LP3 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD6 ankyrin repeat domain 6 22881 B7Z3D2 PAR-CLIP
Ascano M Jr , et al. 2012
ANKRD9 ankyrin repeat domain 9 122416 Q96BM1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKS1A ankyrin repeat and sterile alpha motif domain containing 1A 23294 Q05CP0 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 56899 B7Z9I9 PAR-CLIP
Ascano M Jr , et al. 2012
ANKS6 ankyrin repeat and sterile alpha motif domain containing 6 203286 B3KXP1 PAR-CLIP
Ascano M Jr , et al. 2012
ANKZF1 ankyrin repeat and zinc finger domain containing 1 55139 Q9H8Y5 PAR-CLIP
Ascano M Jr , et al. 2012
ANLN anillin, actin binding protein 54443 Q9NQW6 PAR-CLIP
Ascano M Jr , et al. 2012
ANO4 anoctamin 4 121601 Q32M45 PAR-CLIP
Ascano M Jr , et al. 2012
ANO5 anoctamin 5 203859 Q75V66 PAR-CLIP
Ascano M Jr , et al. 2012
ANO6 anoctamin 6 196527 B3KX12 PAR-CLIP
Ascano M Jr , et al. 2012
ANO8 anoctamin 8 57719 Q9HCE9 PAR-CLIP
Ascano M Jr , et al. 2012
ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 8125 P39687 PAR-CLIP
Ascano M Jr , et al. 2012
ANP32B acidic (leucine-rich) nuclear phosphoprotein 32 family, member B 10541 Q92688 PAR-CLIP
Ascano M Jr , et al. 2012
ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E 81611 Q9BTT0 PAR-CLIP
Ascano M Jr , et al. 2012
ANUBL1 zinc finger, AN1-type domain 4 93550 Q86XD8 PAR-CLIP
Ascano M Jr , et al. 2012
ANXA11 annexin A11 311 P50995 PAR-CLIP
Ascano M Jr , et al. 2012
ANXA2 annexin A2 302 P07355 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANXA5 annexin A5 308 P08758 PAR-CLIP
Ascano M Jr , et al. 2012
ANXA6 annexin A6 309 P08133 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ANXA7 annexin A7 310 P20073 PAR-CLIP
Ascano M Jr , et al. 2012
AOC2 amine oxidase, copper containing 2 (retina-specific) 314 O75106 PAR-CLIP
Ascano M Jr , et al. 2012
AOC3 amine oxidase, copper containing 3 (vascular adhesion protein 1) 8639 Q16853 PAR-CLIP
Ascano M Jr , et al. 2012
AP1AR adaptor-related protein complex 1 associated regulatory protein 55435 Q63HQ0 PAR-CLIP
Ascano M Jr , et al. 2012
AP1G1 adaptor-related protein complex 1, gamma 1 subunit 164 O43747 PAR-CLIP
Ascano M Jr , et al. 2012
AP1M1 adaptor-related protein complex 1, mu 1 subunit 8907 Q59EK3 PAR-CLIP
Ascano M Jr , et al. 2012
AP1M2 adaptor-related protein complex 1, mu 2 subunit 10053 Q9Y6Q5 PAR-CLIP
Ascano M Jr , et al. 2012
AP1S1 adaptor-related protein complex 1, sigma 1 subunit 1174 P61966 PAR-CLIP
Ascano M Jr , et al. 2012
AP1S2 adaptor-related protein complex 1, sigma 2 subunit 8905 P56377 PAR-CLIP
Ascano M Jr , et al. 2012
AP1S3 adaptor-related protein complex 1, sigma 3 subunit 130340 Q96PC3 PAR-CLIP
Ascano M Jr , et al. 2012
AP2M1 adaptor-related protein complex 2, mu 1 subunit 1173 Q96CW1 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
AP2S1 adaptor-related protein complex 2, sigma 1 subunit 1175 P53680 PAR-CLIP
Ascano M Jr , et al. 2012
AP3B1 adaptor-related protein complex 3, beta 1 subunit 8546 E5RJ68 PAR-CLIP
Ascano M Jr , et al. 2012
AP3M1 adaptor-related protein complex 3, mu 1 subunit 26985 Q9Y2T2 PAR-CLIP
Ascano M Jr , et al. 2012
AP3M2 adaptor-related protein complex 3, mu 2 subunit 10947 P53677 PAR-CLIP
Ascano M Jr , et al. 2012
AP3S1 adaptor-related protein complex 3, sigma 1 subunit 1176 Q92572 PAR-CLIP
Ascano M Jr , et al. 2012
AP3S2 adaptor-related protein complex 3, sigma 2 subunit 10239 P59780 PAR-CLIP
Ascano M Jr , et al. 2012
AP4E1 adaptor-related protein complex 4, epsilon 1 subunit 23431 B4DM48 PAR-CLIP
Ascano M Jr , et al. 2012
AP4M1 adaptor-related protein complex 4, mu 1 subunit 9179 O00189 PAR-CLIP
Ascano M Jr , et al. 2012
APAF1 apoptotic peptidase activating factor 1 317 O14727 PAR-CLIP
Ascano M Jr , et al. 2012
APBA2 amyloid beta (A4) precursor protein-binding, family A, member 2 321 Q59G28 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
APBB2 amyloid beta (A4) precursor protein-binding, family B, member 2 323 Q92870 PAR-CLIP
Ascano M Jr , et al. 2012
APEH N-acylaminoacyl-peptide hydrolase 327 P13798 PAR-CLIP
Ascano M Jr , et al. 2012
APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 328 P27695 PAR-CLIP
Ascano M Jr , et al. 2012
APEX2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2 27301 B7ZA71 PAR-CLIP
Ascano M Jr , et al. 2012
APH1A anterior pharynx defective 1 homolog A (C. elegans) 51107 Q96BI3 PAR-CLIP
Ascano M Jr , et al. 2012
APH1B anterior pharynx defective 1 homolog B (C. elegans) 83464 Q8WW43 PAR-CLIP
Ascano M Jr , et al. 2012
API5 apoptosis inhibitor 5 8539 Q9BZZ5 PAR-CLIP
Ascano M Jr , et al. 2012
APIP APAF1 interacting protein 51074 Q96GX9 PAR-CLIP
Ascano M Jr , et al. 2012
APLP2 amyloid beta (A4) precursor-like protein 2 334 Q06481 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
APOA1BP apolipoprotein A-I binding protein 128240 Q8NCW5 PAR-CLIP
Ascano M Jr , et al. 2012
APOBEC3D apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 140564 B2CML4 PAR-CLIP
Ascano M Jr , et al. 2012
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 60489 Q9HC16 PAR-CLIP
Ascano M Jr , et al. 2012
APOLD1 apolipoprotein L domain containing 1 81575 Q96LR9 PAR-CLIP
Ascano M Jr , et al. 2012
APPBP2 amyloid beta precursor protein (cytoplasmic tail) binding protein 2 10513 Q92624 PAR-CLIP
Ascano M Jr , et al. 2012
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 26060 Q9UKG1 PAR-CLIP
Ascano M Jr , et al. 2012
APPL2 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 55198 Q8NEU8 PAR-CLIP
Ascano M Jr , et al. 2012
APRT adenine phosphoribosyltransferase 353 P07741 PAR-CLIP
Ascano M Jr , et al. 2012
APTX aprataxin 54840 Q7Z2E3 PAR-CLIP
Ascano M Jr , et al. 2012
AQR aquarius homolog (mouse) 9716 O60306 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARAF v-raf murine sarcoma 3611 viral oncogene homolog 369 P10398 PAR-CLIP
Ascano M Jr , et al. 2012
ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 116985 Q96P48 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 64411 Q05CH1 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARCN1 archain 1 372 B4E1X2 PAR-CLIP
Ascano M Jr , et al. 2012
ARF1 ADP-ribosylation factor 1 375 Q8N6T3 PAR-CLIP
Ascano M Jr , et al. 2012
ARF4 ADP-ribosylation factor 4 378 P18085 PAR-CLIP
Ascano M Jr , et al. 2012
ARF5 ADP-ribosylation factor 5 381 A4D0Z3 PAR-CLIP
Ascano M Jr , et al. 2012
ARF6 ADP-ribosylation factor 6 382 P62330 PAR-CLIP
Ascano M Jr , et al. 2012
ARFGAP1 ADP-ribosylation factor GTPase activating protein 1 55738 Q8N6T3 PAR-CLIP
Ascano M Jr , et al. 2012
ARFGAP2 ADP-ribosylation factor GTPase activating protein 2 84364 B4DX29 PAR-CLIP
Ascano M Jr , et al. 2012
ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 26286 E9PB03 PAR-CLIP
Ascano M Jr , et al. 2012
ARFGEF2 ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) 10564 Q9Y6D5 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARFIP1 ADP-ribosylation factor interacting protein 1 27236 P53367 PAR-CLIP
Ascano M Jr , et al. 2012
ARFIP2 ADP-ribosylation factor interacting protein 2 23647 P53365 PAR-CLIP
Ascano M Jr , et al. 2012
ARGLU1 arginine and glutamate rich 1 55082 Q9NWB6 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP1 Rho GTPase activating protein 1 392 Q07960 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP10 Rho GTPase activating protein 10 79658 A1A4S6 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP11A Rho GTPase activating protein 11A 9824 Q6P4F7 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP12 Rho GTPase activating protein 12 94134 Q504X1 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP17 Rho GTPase activating protein 17 55114 Q68EM7 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP18 Rho GTPase activating protein 18 93663 Q8N392 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP19 Rho GTPase activating protein 19 84986 Q14CB8 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP22 Rho GTPase activating protein 22 58504 Q7Z5H3 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARHGAP26 Rho GTPase activating protein 26 23092 Q9UNA1 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARHGAP27 Rho GTPase activating protein 27 201176 Q6ZUM4 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP28 Rho GTPase activating protein 28 79822 B4DXL2 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP29 Rho GTPase activating protein 29 9411 Q52LW3 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP31 Rho GTPase activating protein 31 57514 Q2M1Z3 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP35 Rho GTPase activating protein 35 2909 Q9NRY4 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP39 Rho GTPase activating protein 39 80728 B3KS00 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP4 Rho GTPase activating protein 4 393 P98171 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP42 Rho GTPase activating protein 42 143872 A6NI28 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP44 Rho GTPase activating protein 44 9912 Q17R89 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP5 Rho GTPase activating protein 5 394 Q13017 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGAP8 Rho GTPase activating protein 8 23779 P85298 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 396 P52565 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1 9138 Q92888 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 9639 O15013 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF18 Rho/Rac guanine nucleotide exchange factor (GEF) 18 23370 Q6ZSZ5 PAR-CLIP; RNA immunoprecipitation (RIP)
Ascano M Jr , et al. 2012
ARHGEF26 Rho guanine nucleotide exchange factor (GEF) 26 26084 B3KXG0 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 50650 Q9NR81 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF37 Rho guanine nucleotide exchange factor (GEF) 37 389337 A1IGU5 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF40 Rho guanine nucleotide exchange factor (GEF) 40 55701 Q8TER5 PAR-CLIP
Ascano M Jr , et al. 2012
ARHGEF5 Rho guanine nucleotide exchange factor (GEF) 5 7984 Q12774 PAR-CLIP
Ascano M Jr , et al. 2012
ARID3A AT rich interactive domain 3A (BRIGHT-like) 1820 Q99856 PAR-CLIP
Ascano M Jr , et al. 2012
ARID3B AT rich interactive domain 3B (BRIGHT-like) 10620 Q8IVW6 PAR-CLIP
Ascano M Jr , et al. 2012
ARID3C AT rich interactive domain 3C (BRIGHT-like) 138715 A6NKF2 PAR-CLIP
Ascano M Jr , et al. 2012
ARID4A AT rich interactive domain 4A (RBP1-like) 5926 P29374 PAR-CLIP
Ascano M Jr , et al. 2012
ARID4B AT rich interactive domain 4B (RBP1-like) 51742 Q4LE39 PAR-CLIP
Ascano M Jr , et al. 2012
ARID5B AT rich interactive domain 5B (MRF1-like) 84159 Q14865 PAR-CLIP
Ascano M Jr , et al. 2012
ARIH1 ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 (Drosophila) 25820 Q9Y4X5 PAR-CLIP
Ascano M Jr , et al. 2012
ARIH2 ariadne homolog 2 (Drosophila) 10425 O95376 PAR-CLIP
Ascano M Jr , et al. 2012
ARL1 ADP-ribosylation factor-like 1 400 P40616 PAR-CLIP
Ascano M Jr , et al. 2012
ARL10 ADP-ribosylation factor-like 10 285598 Q6PCE2 PAR-CLIP
Ascano M Jr , et al. 2012
ARL13B ADP-ribosylation factor-like 13B 200894 Q3SXY8 PAR-CLIP
Ascano M Jr , et al. 2012
ARL15 ADP-ribosylation factor-like 15 54622 Q9NXU5 PAR-CLIP
Ascano M Jr , et al. 2012
ARL17A ADP-ribosylation factor-like 17A 51326 Q8IVW1 PAR-CLIP
Ascano M Jr , et al. 2012
ARL2 ADP-ribosylation factor-like 2 402 G3V184 PAR-CLIP
Ascano M Jr , et al. 2012
ARL2BP ADP-ribosylation factor-like 2 binding protein 23568 Q9Y2Y0 PAR-CLIP
Ascano M Jr , et al. 2012
ARL4C ADP-ribosylation factor-like 4C 10123 P56559 PAR-CLIP
Ascano M Jr , et al. 2012
ARL5A ADP-ribosylation factor-like 5A 26225 Q9Y689 PAR-CLIP
Ascano M Jr , et al. 2012
ARL5B ADP-ribosylation factor-like 5B 221079 B0YIW9 PAR-CLIP
Ascano M Jr , et al. 2012
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 23204 Q15041 PAR-CLIP
Ascano M Jr , et al. 2012
ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 10550 O75915 PAR-CLIP
Ascano M Jr , et al. 2012
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 151188 B3KMZ5 PAR-CLIP
Ascano M Jr , et al. 2012
ARL8A ADP-ribosylation factor-like 8A 127829 Q96BM9 PAR-CLIP
Ascano M Jr , et al. 2012
ARL8B ADP-ribosylation factor-like 8B 55207 Q9NVJ2 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC1 armadillo repeat containing 1 55156 Q9NVT9 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC10 armadillo repeat containing 10 83787 Q8N2F6 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC4 armadillo repeat containing 4 55130 A8K906 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC5 armadillo repeat containing 5 79798 Q96C12 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC6 armadillo repeat containing 6 93436 Q6NXE6 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC8 armadillo repeat containing 8 25852 B7Z637 PAR-CLIP
Ascano M Jr , et al. 2012
ARMC9 armadillo repeat containing 9 80210 Q7Z3E5 PAR-CLIP
Ascano M Jr , et al. 2012
ARMCX2 armadillo repeat containing, X-linked 2 9823 Q7L311 PAR-CLIP
Ascano M Jr , et al. 2012
ARMCX3 armadillo repeat containing, X-linked 3 51566 Q9UH62 PAR-CLIP
Ascano M Jr , et al. 2012
ARMCX4 armadillo repeat containing, X-linked 4 100131755 F8W8Y7 PAR-CLIP
Ascano M Jr , et al. 2012
ARNT aryl hydrocarbon receptor nuclear translocator 405 P27540 PAR-CLIP
Ascano M Jr , et al. 2012
ARNTL2 aryl hydrocarbon receptor nuclear translocator-like 2 56938 Q8WYA1 PAR-CLIP
Ascano M Jr , et al. 2012
ARPC1A actin related protein 2/3 complex, subunit 1A, 41kDa 10552 Q92747 PAR-CLIP
Ascano M Jr , et al. 2012
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 10095 A4D275 PAR-CLIP
Ascano M Jr , et al. 2012